var title_f6_32_6656="Alpha and beta globin gene clusters";
var content_f6_32_6656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 496px\">",
"   <div class=\"ttl\">",
"    Alpha and beta globin gene clusters in man",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 476px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the alpha (lower) and beta (upper) globin gene clusters in man, showing the position of the various genes, as well as the locus control region (LCR) for the beta globin gene cluster and the various hypersensitive sites for the beta globin gene cluster (HS 1 to 5) and the alpha gene cluster (HS-40). The only genes active after birth in the beta globin gene cluster are those for G(gamma), A(gamma), delta, and beta globin, while those active after birth in the alpha globin gene cluster are the two alpha genes (alpha 2 and alpha 1). The hemoglobin A tetramer (HbA) shown between the two clusters is formed from the products of the beta globin gene (on chromosome 11) and the two alpha globin genes (on chromosome 16).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure drawn by Dr. Ross Hardison and reproduced with permission from the Globin Gene Server, which can be found at: &lt;file://globin.cse.psu.edu&gt;.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6656=[""].join("\n");
var outline_f6_32_6656=null;
var title_f6_32_6657="Uterine artery ligation";
var content_f6_32_6657=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Uterine artery ligation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sutures are placed to ligate the ascending uterine artery and the anastomotic branch of the ovarian artery. The procedure should be performed on each side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6657=[""].join("\n");
var outline_f6_32_6657=null;
var title_f6_32_6658="Stenosis after gastric sleeve";
var content_f6_32_6658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Stenosis after gastric sleeve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This film shows a proximal sleeve dilatation due to distal sleeve stenosis. The patient was subsequently converted to a Roux-en-Y gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Raul J Rosenthal, MD, FACS, FASMBS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6658=[""].join("\n");
var outline_f6_32_6658=null;
var title_f6_32_6659="Trace metals: Patient drug information";
var content_f6_32_6659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Trace metals: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/40/34435?source=see_link\">",
"     see \"Trace metals: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/41/1686?source=see_link\">",
"     see \"Trace metals: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Multitrace&reg;-4;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Concentrate;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Neonatal;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Pediatric;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5 Concentrate;",
"     </li>",
"     <li>",
"      Trace Elements 4 Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701800",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chromium, copper, iodide, manganese, molybdenum, selenium, zinc, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to benzyl alcohol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12139 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6659=[""].join("\n");
var outline_f6_32_6659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012603\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012602\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012606\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012607\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012609\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012605\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012611\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/40/34435?source=related_link\">",
"      Trace metals: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/41/1686?source=related_link\">",
"      Trace metals: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6660="Prilocaine: Drug information";
var content_f6_32_6660=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prilocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30163?source=see_link\">",
"    see \"Prilocaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Plain Dental",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest&reg; Plain",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia:",
"     </b>",
"     Infiltration, or conduction block: Initial: 40-80 mg (1-2 mL) as a 4% solution; up to a maximum of 400 mg (10 mL) as a 4% solution within a 2-hour period. Manufacturer's maximum recommended dose is not more than 600 mg to normal healthy adults. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and children doses of prilocaine hydrochloride cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 139.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dental anesthesia:",
"     </b>",
"     Infiltration, or conduction block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &lt;10 years:",
"     </i>",
"     Doses &gt;40 mg (1 mL) as a 4% solution per procedure rarely needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;10 years and Adults:",
"     </i>",
"     Initial: 40-80 mg (1-2 mL) as a 4% solution; up to a maximum of 400 mg (10 mL) as a 4% solution within a 2-hour period. Manufacturer's maximum recommended dose is not more than 600 mg to normal healthy adults. The effective anesthetic dose varies with procedure, intensity of anesthesia needed, duration of anesthesia required and physical condition of the patient. Always use the lowest effective dose along with careful aspiration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Adult and children doses of prilocaine hydrochloride cited from USP Dispensing Information (USP DI), 17th ed, The United States Pharmacopeial Convention, Inc, Rockville, MD, 1997, 139.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [for dental use]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citanest&reg; Plain Dental: 4% [40 mg/mL] (1.8 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14936535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Amide-type anesthetic used for local infiltration anesthesia; injection near nerve trunks to produce nerve block",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prilocaine may be confused with Polocaine&reg;, PriLOSEC&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, aseptic meningitis resulting in paralysis, chills, CNS stimulation followed by CNS depression, miosis, nausea, skin discoloration, tinnitus, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to local anesthetics of the amide type or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Has been reported with prilocaine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; reduce dose consistent with age and physical status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Dental practitioners using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methemoglobinemia Associated Agents: May enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F213175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Usual infiltration doses of prilocaine given to nursing mothers has not been shown to affect the health of the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F213176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Citanest (BE, ES, FI, GB, LU, NL, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Citanest Dental (AU);",
"     </li>",
"     <li>",
"      Xylonest (CH, DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetics bind selectively to the intracellular surface of sodium channels to block influx of sodium into the axon. As a result, depolarization necessary for action potential propagation and subsequent nerve function is prevented. The block at the sodium channel is reversible. When drug diffuses away from the axon, sodium channel function is restored and nerve propagation returns.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Infiltration: ~2 minutes; Inferior alveolar nerve block: ~3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Infiltration: Complete anesthesia for procedures lasting 20 minutes; Inferior alveolar nerve block: ~2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.7-4.4 L/kg; crosses blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10-150 minutes; prolonged with hepatic or renal impairment",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/32/6660/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacKenzie TA and Young ER, &ldquo;Local Anesthetic Update,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1993, 40(2):29-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/32/6660/abstract-text/8185087/pubmed\" id=\"8185087\" target=\"_blank\">",
"        8185087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore PA and Hersh EV, \"Local Anesthetics: Pharmacology and Toxicity,\"",
"      <i>",
"       Dent Clin North Am",
"      </i>",
"      , 2010, 54(4):587-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/32/6660/abstract-text/20831923/pubmed\" id=\"20831923\" target=\"_blank\">",
"        20831923",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo;",
"      <i>",
"       Gen Dent",
"      </i>",
"      , 1994, 42(1):16, 18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/32/6660/abstract-text/7911769/pubmed\" id=\"7911769\" target=\"_blank\">",
"        7911769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yagiela JA, &ldquo;Local Anesthetics,&rdquo;",
"      <i>",
"       Anesth Prog",
"      </i>",
"      , 1991, 38(4-5):128-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/32/6660/abstract-text/1819966/pubmed\" id=\"1819966\" target=\"_blank\">",
"        1819966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10228 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-5B41D960F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6660=[""].join("\n");
var outline_f6_32_6660=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213183\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213184\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213203\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213185\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213193\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213186\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213170\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213159\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14936535\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213208\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213201\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213173\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213163\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299942\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213167\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213168\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079713\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213175\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213176\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213162\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213172\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10228\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10228|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30163?source=related_link\">",
"      Prilocaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6661="Moexipril: Patient drug information";
var content_f6_32_6661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Moexipril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/53/1880?source=see_link\">",
"     see \"Moexipril: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Univasc&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to moexipril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10874 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-01FC61200C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6661=[""].join("\n");
var outline_f6_32_6661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020725\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020727\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020726\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020731\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020732\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020734\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020729\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020730\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020735\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020736\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/53/1880?source=related_link\">",
"      Moexipril: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6662="Model pathogenesis IPF";
var content_f6_32_6662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64611&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Conceptual pathogenesis of idiopathic pulmonary fibrosis: Key role of the fibroblast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a genetically predisposed host (eg, telomerase mutation/deficiency), recurrent injury disrupts the alveolar epithelium and basement membrane, and activates cells within the alveolar wall to release proinflammatory cytokines and chemokines, including TNF-alpha, IL-1, and MCP-1. These soluble mediators may activate residential and/or recruit circulating cells including fibrocytes, thus perpetuating the response to recurrent insults. Profibrogenic molecules, such as PDGF and TGF-beta, are also secreted by inflammatory, epithelial, and endothelial cells. Fibroblasts respond to these changes in one of several ways: they may increase in number, they may differentiate into myofibroblasts and actively synthesize collagen; or they may undergo further differentiation, resulting in the expression of unique cell surface receptors. Increased collagen synthesis, coupled with decreased degradation, causes excessive and abnormal collagen deposition. The resulting aggregates, composed of mesenchymal cells and newly synthesized collagen, are called \"fibrotic foci\". Progressive deposition of extracellular matrix leads to distorted pulmonary architecture with loss of capillary surface area and gas exchange units; the resulting honeycomb fibrotic lung has no potential for regeneration and repair.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ganesh Raghu, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6662=[""].join("\n");
var outline_f6_32_6662=null;
var title_f6_32_6663="Atrial fibrillation 1";
var content_f6_32_6663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1121px;\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 90px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lead V1 showing coarse atrial fibrillation with moderate ventricular response. The two characteristic findings in AF are present: the very rapid atrial fibrillatory waves (f waves) which are variable in appearance; and the irregularly irregular ventricular response as the R-R interval between beats is unpredictable. Coarse atrial fibrillation may appear similar to atrial flutter. However, the variable height and duration of the f waves differentiate them from atrial flutter (F) waves which are identical in appearance and occur at a constant rate of about 250 to 350 beats/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6663=[""].join("\n");
var outline_f6_32_6663=null;
var title_f6_32_6664="Perioperative nutritional support";
var content_f6_32_6664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Perioperative nutritional support",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Kathleen M Fairfield, MD, DrPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Reza Askari, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6664/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/32/6664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 4, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition in hospitalized patients is well documented in the literature with rates up to 50 percent in certain populations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/1\">",
"     1",
"    </a>",
"    ]. The notion that malnutrition affects outcomes in surgical patients was first reported in 1936 in a study showing that malnourished patients undergoing ulcer surgery had a 33 percent mortality rate compared with 3.5 percent in well nourished individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/2\">",
"     2",
"    </a>",
"    ]. A prospective study of 500 patients admitted to a teaching hospital in England found that 40 percent of patients were undernourished on presentation, and patients lost an average of 5.4 percent of their body weight during their hospital stay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/3\">",
"     3",
"    </a>",
"    ]. Nutritional support may be indicated for malnourished individuals requiring surgical intervention; however, it is often unclear when to intervene.",
"   </p>",
"   <p>",
"    The preoperative nutritional assessment of surgical patients, options for nutritional support and potential benefits are reviewed here. An overview of parenteral and enteral nutrition is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF MALNUTRITION IN SURGICAL PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced food intake results in loss of fat, muscle, skin, and ultimately bone and viscera, with subsequent weight loss and an increase in extracellular fluid volume [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/4\">",
"     4",
"    </a>",
"    ]. Nutritional requirements fall as an individual's body mass decreases, probably reflecting more efficient utilization of ingested food and a reduction in work capacity at the cellular level. However, the combination of decreased tissue mass and reduction in work capacity impedes normal homeostatic responses to stressors such as critical illness or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The stress of surgery or trauma increases protein and energy requirements by creating a hypermetabolic, catabolic state [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/6\">",
"     6",
"    </a>",
"    ]. A redistribution of macronutrients (fat, protein, and glycogen) from the labile reserves of adipose tissue and skeletal muscle to more metabolically active tissues such as liver, bone, and visceral organs occurs. This response can lead to the onset of protein calorie malnutrition (defined as a negative balance of 100 g of nitrogen and 10,000 kcal) within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/7\">",
"     7",
"    </a>",
"    ]. The rate of development of malnutrition in critically ill patients is a function of their preexisting nutritional status and their degree of hypermetabolism.",
"   </p>",
"   <p>",
"    Malnutrition causes a number of negative consequences, including [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/4,5,8,9\">",
"     4,5,8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased susceptibility to infection",
"     </li>",
"     <li>",
"      Poor wound healing",
"     </li>",
"     <li>",
"      Increased frequency of decubitus ulcers",
"     </li>",
"     <li>",
"      Overgrowth of bacteria in the gastrointestinal tract",
"     </li>",
"     <li>",
"      Abnormal nutrient losses through the stool",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of particular concern for patients undergoing surgery are the risks of postoperative infection and poor wound healing. Malnutrition leads to immune system dysfunction by impairing complement activation and production, bacterial opsonization, and the function of neutrophils, macrophages, and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/9\">",
"     9",
"    </a>",
"    ]. One series of underfed patients found subnormal skin reactions to Candida and low levels of antibodies to various phytomitogens, suggesting that humoral and cell mediated immunity are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary immune deficiency due to miscellaneous causes\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with protein energy malnutrition also have slower rates of wound healing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/11\">",
"     11",
"    </a>",
"    ], although most wounds will eventually heal on their own [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/12\">",
"     12",
"    </a>",
"    ]. Additional adverse effects associated with malnutrition were identified in a study of 2743 patients undergoing cardiothoracic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with preoperative hypoalbuminemia alone or in association with chronic liver disease or heart failure were more likely to have postoperative organ dysfunction (cardiac, pulmonary, renal, hepatic, neurologic), gastrointestinal bleeding, nosocomial infections, increased days on &nbsp;mechanical ventilation and length of stay in the intensive care unit, and inpatient death. A body mass index (BMI) &lt;20",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    was associated with lower morbidity and mortality compared with a higher BMI, but this finding contrasts with other studies. BMI is an imperfect measure of nutritional status and should be combined with other clinical indicators.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUTRITIONAL ASSESSMENT IN THE SURGICAL PATIENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task of the consultant considering perioperative nutritional recommendations is to assess the patient's underlying nutritional status. Several aspects of the past medical history are of particular importance, including chronic disease, infection, recent hospitalization, and prior surgery (particularly gastrointestinal surgery). The details of the current hospitalization will also play a central role. Newly admitted trauma patients who are otherwise well have drastically different needs from patients who have had surgery several weeks in the past but have remained hospitalized due to complications.",
"   </p>",
"   <p>",
"    A family history of diabetes, cardiovascular disease, inflammatory bowel disease, or celiac disease should be determined. Important aspects of the social history include socioeconomic status and substance use including alcohol, tobacco, and illicit drugs. It may be useful to determine whether the patient does",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    own shopping and cooking, or whether",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    has a spouse, child, or other caregiver to assist with care.",
"   </p>",
"   <p>",
"    In addition to collecting information on current medications, the consultant should inquire about vitamin, mineral, herbal, or probiotic supplements (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     lactobacillus",
"    </a>",
"    ). Lastly, use of dietary supplements such as protein shakes, Ensure, or Boost should be determined. Any allergies or food intolerances also should be noted.",
"   </p>",
"   <p>",
"    On review of systems, a history of weight loss or gain is important. It may be helpful to assess greatest and least adult weights, and \"usual\" current weight. Any recent losses or gains (and whether they were purposeful or not) prior to the hospital stay should be assessed, as well as weight changes during the hospitalization. Additional important questions include the need for dentures, and gastrointestinal symptoms (nausea, anorexia, vomiting, diarrhea or constipation). &nbsp;",
"   </p>",
"   <p>",
"    Several clinical tools are available to quickly assess and score nutrition status. The Subjective Global Assessment of Nutritional Status is a brief tool that includes history and physical examination findings and allows standardized assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/14\">",
"     14",
"    </a>",
"    ]. The Nutritional Risk Screening tool (NRS 2002) can be applied rapidly and used to screen for poor baseline nutritional status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diet history should be collected from the patient, family, or care facility. Although there are several methods of dietary assessment, the most useful and straightforward for the consultant may be to assess the usual intake on an average day before hospitalization or before the onset of the current illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to vital signs and a general physical examination, the following should be assessed (",
"    <a class=\"graphic graphic_table graphicRef78426 \" href=\"UTD.htm?1/19/1341\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Height and weight (calculate BMI using weight in kg divided by height in meters squared (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      ), or using a nomogram) (",
"      <a class=\"graphic graphic_figure graphicRef65305 \" href=\"UTD.htm?12/3/12351\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      General: Loss of subcutaneous tissue",
"     </li>",
"     <li>",
"      Head and neck exam: Hair loss, bitemporal wasting, conjunctival pallor, xerosis, glossitis, bleeding or sores on the gums and oral mucosa, angular cheilosis or stomatitis, dentition",
"     </li>",
"     <li>",
"      Cardiovascular: Evidence of heart failure or high-output state",
"     </li>",
"     <li>",
"      Neck: Thyromegaly",
"     </li>",
"     <li>",
"      Extremities: Edema, muscle wasting",
"     </li>",
"     <li>",
"      Neurologic: Evidence of peripheral neuropathy, reflexes, tetany, mental status",
"     </li>",
"     <li>",
"      Skin: Ecchymoses, petechiae, pallor, pressure ulcers, assessment of surgical wound healing and signs of wound infection (if postoperative).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of overall nutritional status is best accomplished by the history and physical examination, though some laboratory tests lend additional information.",
"   </p>",
"   <p>",
"    Because of the close relationship between protein status and wound healing, and because protein-calorie malnutrition can be treated with supplementation (see below), assessing protein status is particularly important in the surgical patient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Protein status is affected by previous intake, muscle mass, duration of current illness, blood loss, wound healing, infections, and gastrointestinal absorption.",
"   </p>",
"   <p>",
"    Three serum measures of protein status have differing half-lives. These serum components do not directly indicate nutritional status, but may rather reflect the severity of illness and must be used in conjunction with other clinical data such as the duration of the current surgical illness to be useful in determining therapy. Although decreased levels for these protein markers correlate with adverse outcomes, improvements in these markers with nutritional supplementation are not reliably associated with a clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Outcomes with nutritional intervention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum albumin has the longest half-life at 18 to 20 days and is the most extensively used parameter. Low serum albumin (&lt;2.2",
"      <span class=\"nowrap\">",
"       g/dL)",
"      </span>",
"      is a marker of a negative catabolic state, and a predictor of poor outcome. Surgery decreases serum albumin levels, as do other acute stresses, and hepatic and renal diseases.",
"     </li>",
"     <li>",
"      Serum transferrin has an intermediate half-life of eight to nine days, reflecting protein status over the past two to four weeks. Transferrin also reflects iron status, and low transferrin should be considered an indicator of protein status only in the setting of normal serum iron.",
"     </li>",
"     <li>",
"      Serum prealbumin (transthyretin) has the shortest half-life at two to three days. Although prealbumin responds quickly to the onset of malnutrition and rises rapidly with adequate protein intake, the level can be altered in the acute phase response due to acute or chronic inflammation. In general, inflammatory cytokines reduce the level of prealbumin synthesis by the liver and it can also be reduced with renal and hepatic disease. Therefore, it is the least helpful of the three for assessing overall nutritional status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these measures, a few other laboratory tests may be helpful. Electrolytes, glucose, and",
"    <span class=\"nowrap\">",
"     BUN/creatinine",
"    </span>",
"    will help assess overall clinical and volume status and are necessary if parenteral nutrition (hyperalimentation) will be instituted. Iron levels should be measured in the setting of unexplained anemia, as should specific vitamin levels if clinically indicated",
"    <span class=\"nowrap\">",
"     (B12/folate",
"    </span>",
"    in macrocytic anemias, others based upon specific physical signs). Serum calcium, magnesium, and phosphorous should also be assessed periodically, particularly in the setting of poor oral intake or diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NUTRITIONAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the presence of malnutrition is established, or it becomes clear that the patient is not able to take adequate oral nutrition, there are several possible nutritional interventions.",
"   </p>",
"   <p>",
"    The general indications for artificial nutritional support include preexisting nutritional deprivation, anticipated or actual inadequate energy intake by mouth, and significant multiorgan system disease. The discussion presented here focuses on surgical patients during the perioperative period. Nutritional issues in critically ill patients and burn patients are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who will undergo gastrointestinal surgery are at a nutritional disadvantage since the postoperative delivery of nutrients via the gut, which is the optimal route, may be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. Early enteral nutrition (oral, tube feeding) is advocated for many surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A Cochrane review and metaanalysis from 2006 updated in 2011 identified no obvious advantage to the routine practice of maintaining patients &lsquo;nil per mouth&rsquo; postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/25\">",
"     25",
"    </a>",
"    ]. The review identified 14 trials that included 1224 patients undergoing predominantly colorectal surgery. No significant differences were identified in the risk of intraabdominal abscess, anastomotic",
"    <span class=\"nowrap\">",
"     leak/dehiscence,",
"    </span>",
"    or pneumonia for patients started on early oral nutrition (initiated within 24 hours of surgery) compared with traditional surgical care (ie, no nutrition or oral nutrition when tolerated). Length of hospital stay and the incidence of postoperative wound infection were also similar. A metaanalysis of six of the trials found a slightly increased risk of vomiting (risk ratio 1.27, 95% CI, 1.01-1.61). The higher incidence of vomiting reported in the early feeding group did not appear to be related to oral intake compared with tube feeding. No additional information was given regarding the type of surgery (open versus laparoscopic), or perioperative pain management (eg, opioid or antiemetic use).",
"   </p>",
"   <p>",
"    Parenteral support is indicated in postoperative patients who are unable to receive adequate enteral nutrition by postoperative days 10 to 14 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/20,26\">",
"     20,26",
"    </a>",
"    ]. Earlier intervention may be appropriate in patients who are malnourished at baseline, or who have a complicated postoperative course [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/19\">",
"     19",
"    </a>",
"    ]. If at least one of the following criteria listed below is present, the patient is considered to be malnourished [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss &gt;10 to 15 percent within six months",
"     </li>",
"     <li>",
"      BMI &lt;18",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Subjective global assessment, Grade C",
"     </li>",
"     <li>",
"      Serum albumin &lt;30",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"      (with no evidence of hepatic or renal dysfunction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients undergoing bowel surgery for gastrointestinal malignancy, malignancy-related metabolic changes may suggest the need for earlier intervention.",
"   </p>",
"   <p>",
"    Patients with inflammatory bowel disease are at particularly increased risk of being malnourished when undergoing surgical procedures. A period of bowel rest (nil per mouth) may be appropriate in patients with disease that is severe enough to require surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=see_link\">",
"     \"Nutrition and dietary interventions in adults with inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OUTCOMES WITH NUTRITIONAL INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it seems intuitive that feeding malnourished patients perioperatively should improve outcomes, there are risks specific to each route of nutritional support, and these risks plus the added cost must be balanced with the potential benefit. Although a significant quantity of literature addresses nutritional interventions and outcomes, the majority of trials are small, most are not randomized, controlled trials, and the definition and measures of malnutrition vary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Parenteral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several metaanalyses have evaluated the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    in the perioperative period, and have come to inconsistent conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/28-30\">",
"     28-30",
"    </a>",
"    ], based on inclusion of different studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One systematic review found that preoperative parenteral nutrition (13 randomized trials) decreased postoperative complications by 10 percent, while postoperative parenteral nutrition alone (8 randomized trials) resulted in a 10 percent increase in complication rates [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/30\">",
"       30",
"      </a>",
"      ]. These findings were not confirmed by a subsequent metaanalysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another metaanalysis (26 randomized trials, although 3 were not in surgical patients) found that parenteral nutrition decreased hospital complications in studies where lipid-free solutions were used, and for patients who were malnourished (not consistently defined) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/28\">",
"       28",
"      </a>",
"      ]. These findings were also not confirmed by another study, which found greater benefit for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      in trials where lipids were used, and in trials evaluating well-nourished patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The largest metaanalysis included 41 trials of parenteral nutrition, provided before",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/29\">",
"       29",
"      </a>",
"      ]. Parenteral nutrition had no effect on postoperative mortality; there was no significant effect on postoperative complication rates, although trends for all evaluated outcomes favored parenteral nutrition over no nutrition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies also evaluated whether particular subgroups might benefit from perioperative parenteral nutrition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early study suggested that parenteral nutrition was beneficial in patients with upper gastrointestinal malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. Mortality and postoperative complications were decreased in a group of patients with gastrointestinal malignancies and weight loss (minimum 10 percent) who received 10 days of preoperative parenteral nutrition and 9 days of postoperative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      , compared with control patients who did not receive preoperative parenteral nutrition and were only partially supplemented postoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/33\">",
"       33",
"      </a>",
"      ]. Preoperative treatment with parenteral nutrition also decreased morbidity in a group of patients undergoing resection for hepatocellular cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=see_link\">",
"       \"The role of parenteral and enteral/oral nutritional support in patients with cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The VA Cooperative study randomly assigned patients to parenteral nutrition for seven days preoperatively and three days postoperatively or to control groups who either received no nutrition or were fed enterally [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/35\">",
"       35",
"      </a>",
"      ]. Overall, patients who received parenteral nutrition had a higher rate of infectious complications (14.1 versus 6.4 percent) and a nonsignificant reduction in mortality (7.3 percent versus 4.9 percent at 30 days). In the severely malnourished subgroup, however, those treated with parenteral nutrition had fewer major postoperative complications than controls (20 to 25 percent versus 40 to 50 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Enteral feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative enteral nutrition may decrease the incidence of infectious complications but not in other outcomes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A metaanalysis evaluated 44 randomized trials of enteral nutrition in the perioperative period [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/36\">",
"       36",
"      </a>",
"      ]. Trials were grouped into three comparisons: enteral nutrition versus no artificial nutrition, enteral nutrition versus parenteral nutrition, and volitional nutritional supplements (oral supplemental feeding) versus no artificial nutrition. There were no mortality differences for any of the comparator groups [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/36\">",
"       36",
"      </a>",
"      ]. Compared with no artificial nutrition, enteral nutrition recipients had fewer infections (absolute risk -11 percent, 95% CI -20 to -1 percent) but there was no significant impact on duration of hospitalization or the incidence of wound complications.",
"      <br/>",
"      <br/>",
"      Patients who received volitional nutrition supplements, compared with no supplements, also had a decreased infection rate (absolute risk -10 percent; -19 to -1) and a shorter length of hospital stay by two days (-3.37 to -0.72). The beneficial effect of these supplements was limited to trials studying use in the postoperative period. However, the quality of the trials was low, and one high-quality trial did not observe significant differences in hospital stay [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another metaanalysis comparing enteral nutrition within 24 hours of gastrointestinal surgery compared with traditional postoperative management showed a 45 percent decrease in the risk of overall postoperative complications in those patients receiving early postoperative feeding. There were no differences in the incidence of anastomotic dehiscence, length of stay, or mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Immunonutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the complex interactions between nutrition, mucosal barrier function, immunoregulation, and severe illness become clearer, the hope is that tailored forms of nutritional support may become available and provide benefit for specific disease states. Many new formulas contain nutrients previously considered nonessential. Examples include arginine, glutamine, RNA nucleotides, and omega-3 fatty acids. During an episode of critical illness, these nutrients may become \"conditionally essential.\" The use of enteral formulas that are supplemented with these components is often referred to as immunonutrition.",
"   </p>",
"   <p>",
"    Several metaanalyses have evaluated supplementation with arginine, glutamine, nonessential fatty acids, branched chain fatty acids, and RNA in surgical and critically-ill patients. Reductions in infectious complications and length of hospital stay have been found, but without an effect on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Small studies of individual and combinations of components of immunonutrition have also demonstrated no survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. However, the quality of studies evaluating immunonutrition is variable and the authors of the metaanalyses note methodological flaws in the individual studies. The various metaanalyses are yielding inconsistent results and are not of sufficient strength to make reliable clinical recommendations. Higher quality evidence demonstrating unequivocal benefit is needed before immunotherapy can be recommended as a routine addition to nutritional supplementation in surgical patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The metaanalysis evaluating the largest number of surgical studies (nine randomized trials in elective surgical patients) found that patients who were treated with supplemental glutamine had a significantly reduced incidence of infectious complications (RR 0.53, 95% CI 0.42-0.68), and reduced length of stay (-3.34, 95% CI -4.45 to -2.23) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another metaanalysis of 24 studies (including critically-ill, trauma, and burn patients) found that dietary supplementation with fish oil was most consistently associated with reduced infectious complications in the critically ill patients only, without a clear benefit for arginine or glutamine [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6664/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malnutrition is a prevalent condition with important implications for patients undergoing surgery. The consultant asked to evaluate the patient for possible intervention should first assess the patient's nutritional status by performing a history and physical examination. Judicious use of laboratory tests aimed at assessing protein status is useful. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Consequences of malnutrition in surgical patients'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Nutritional assessment in the surgical patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies regarding outcomes of nutritional interventions in the perioperative period are numerous but are of low quality, and comparisons are difficult to make given the broad range of surgical settings and interventions. However, our general recommendations are as follows: (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nutritional intervention'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Outcomes with nutritional intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For many patients undergoing surgery, early enteral nutrition (&lt;24 hours) is possible and is associated with beneficial effects. Whenever possible, enteral nutrition (oral or tube feeds) should be instituted, unless there is a specific contraindication.",
"     </li>",
"     <li>",
"      For patients with a more delayed return of gut function, postoperative parenteral nutrition is not indicated unless bowel function is not anticipated to return for more than 10 days. Earlier intervention may be appropriate in patients who are severely malnourished at baseline, or who have a complicated postoperative course.",
"     </li>",
"     <li>",
"      For patients who are not malnourished or who have mild-to-moderate malnutrition, surgery should not be delayed for preoperative parenteral or enteral supplementation.",
"     </li>",
"     <li>",
"      Patients with severe malnutrition may derive some benefit from delaying surgery to be fed, but are at increased risk for infectious complications if treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"       total parenteral nutrition",
"      </a>",
"      perioperatively. Patients will benefit more from enteral feeding, when possible.",
"     </li>",
"     <li>",
"      The role for immunonutrition is unclear; thus far, there is insufficient high quality evidence to suggest any specific amino acid or fish oil supplementation for all surgical patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10165566\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to acknowledge Dr. Anjala Tess, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/1\">",
"      Weinsier RL, Hunker EM, Krumdieck CL, Butterworth CE Jr. Hospital malnutrition. A prospective evaluation of general medical patients during the course of hospitalization. Am J Clin Nutr 1979; 32:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/2\">",
"      Studley, HO. Percentage of weight loss: A basic indicator of surgical risk in patients with chronic peptic ulcer. JAMA 1936; 106:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/3\">",
"      McWhirter JP, Pennington CR. Incidence and recognition of malnutrition in hospital. BMJ 1994; 308:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/4\">",
"      Elwyn DH, Bryan-Brown CW, Shoemaker WC. Nutritional aspects of body water dislocations in postoperative and depleted patients. Ann Surg 1975; 182:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/5\">",
"      Kinney JM, Weissman C. Forms of malnutrition in stressed and unstressed patients. Clin Chest Med 1986; 7:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/6\">",
"      Kiyama T, Witte MB, Thornton FJ, Barbul A. The route of nutrition support affects the early phase of wound healing. JPEN J Parenter Enteral Nutr 1998; 22:276.",
"     </a>",
"    </li>",
"    <li>",
"     Babineau TJ, Borlase BC, Blackburn GL. Applied Total Parental Nutrition in the Critically Ill. In: Intensive Care Medicine, Rippe JM, Irwin RS, Alpert JS, Fink MP (Eds), Little, Brown and Co, Boston 1991. p.1675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/8\">",
"      Santos JI. Nutrition, infection, and immunocompetence. Infect Dis Clin North Am 1994; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/9\">",
"      Mainous MR, Deitch EA. Nutrition and infection. Surg Clin North Am 1994; 74:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/10\">",
"      Law DK, Dudrick SJ, Abdou NI. Immunocompetence of patients with protein-calorie malnutrition. The effects of nutritional repletion. Ann Intern Med 1973; 79:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/11\">",
"      Haydock DA, Hill GL. Impaired wound healing in surgical patients with varying degrees of malnutrition. JPEN J Parenter Enteral Nutr 1986; 10:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/12\">",
"      Albina JE. Nutrition and wound healing. JPEN J Parenter Enteral Nutr 1994; 18:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/13\">",
"      Rady MY, Ryan T, Starr NJ. Clinical characteristics of preoperative hypoalbuminemia predict outcome of cardiovascular surgery. JPEN J Parenter Enteral Nutr 1997; 21:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/14\">",
"      Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987; 11:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/15\">",
"      Kondrup J, Rasmussen HH, Hamberg O, et al. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr 2003; 22:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/16\">",
"      Reinhardt GF, Myscofski JW, Wilkens DB, et al. Incidence and mortality of hypoalbuminemic patients in hospitalized veterans. JPEN J Parenter Enteral Nutr 1980; 4:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/17\">",
"      McClave SA, Snider HL, Spain DA. Preoperative issues in clinical nutrition. Chest 1999; 115:64S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/18\">",
"      Seres DS. Surrogate nutrition markers, malnutrition, and adequacy of nutrition support. Nutr Clin Pract 2005; 20:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/19\">",
"      Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Summary of a conference sponsored by the National Institutes of Health, American Society for Parenteral and Enteral Nutrition, and American Society for Clinical Nutrition. Am J Clin Nutr 1997; 66:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/20\">",
"      Souba WW. Nutritional support. N Engl J Med 1997; 336:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/21\">",
"      Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. Ann Surg 1992; 216:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/22\">",
"      Bower RH, Talamini MA, Sax HC, et al. Postoperative enteral vs parenteral nutrition. A randomized controlled trial. Arch Surg 1986; 121:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/23\">",
"      Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg 1992; 215:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/24\">",
"      Shrikhande SV, Shetty GS, Singh K, Ingle S. Is early feeding after major gastrointestinal surgery a fashion or an advance? Evidence-based review of literature. J Cancer Res Ther 2009; 5:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/25\">",
"      Andersen HK, Lewis SJ, Thomas S. Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications. Cochrane Database Syst Rev 2006; :CD004080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/26\">",
"      Sandstr&ouml;m R, Drott C, Hyltander A, et al. The effect of postoperative intravenous feeding (TPN) on outcome following major surgery evaluated in a randomized study. Ann Surg 1993; 217:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/27\">",
"      Braga M, Ljungqvist O, Soeters P, et al. ESPEN Guidelines on Parenteral Nutrition: surgery. Clin Nutr 2009; 28:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/28\">",
"      Heyland DK, Montalvo M, MacDonald S, et al. Total parenteral nutrition in the surgical patient: a meta-analysis. Can J Surg 2001; 44:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/29\">",
"      Koretz RL, Lipman TO, Klein S, American Gastroenterological Association. AGA technical review on parenteral nutrition. Gastroenterology 2001; 121:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/30\">",
"      Klein S, Kinney J, Jeejeebhoy K, et al. Nutrition support in clinical practice: review of published data and recommendations for future research directions. Clin Nutr 1997; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/31\">",
"      M&uuml;ller JM, Brenner U, Dienst C, Pichlmaier H. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982; 1:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/32\">",
"      M&uuml;ller JM, Keller HW, Brenner U, et al. Indications and effects of preoperative parenteral nutrition. World J Surg 1986; 10:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/33\">",
"      Bozzetti F, Gavazzi C, Miceli R, et al. Perioperative total parenteral nutrition in malnourished, gastrointestinal cancer patients: a randomized, clinical trial. JPEN J Parenter Enteral Nutr 2000; 24:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/34\">",
"      Fan ST, Lo CM, Lai EC, et al. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/35\">",
"      Perioperative total parenteral nutrition in surgical patients. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group. N Engl J Med 1991; 325:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/36\">",
"      Koretz RL, Avenell A, Lipman TO, et al. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol 2007; 102:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/37\">",
"      Osland E, Yunus RM, Khan S, Memon MA. Early versus traditional postoperative feeding in patients undergoing resectional gastrointestinal surgery: a meta-analysis. JPEN J Parenter Enteral Nutr 2011; 35:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/38\">",
"      Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome. Crit Care Med 1999; 27:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/39\">",
"      Heyland DK, Novak F, Drover JW, et al. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/40\">",
"      Zheng YM, Li F, Zhang MM, Wu XT. Glutamine dipeptide for parenteral nutrition in abdominal surgery: a meta-analysis of randomized controlled trials. World J Gastroenterol 2006; 12:7537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/41\">",
"      Senkal M, Mumme A, Eickhoff U, et al. Early postoperative enteral immunonutrition: clinical outcome and cost-comparison analysis in surgical patients. Crit Care Med 1997; 25:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/42\">",
"      Senkal M, Zumtobel V, Bauer KH, et al. Outcome and cost-effectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery: a prospective randomized study. Arch Surg 1999; 134:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/43\">",
"      Gianotti L, Braga M, Nespoli L, et al. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology 2002; 122:1763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/44\">",
"      Braga M, Gianotti L, Nespoli L, et al. Nutritional approach in malnourished surgical patients: a prospective randomized study. Arch Surg 2002; 137:174.",
"     </a>",
"    </li>",
"    <li>",
"     Okabayashi, T, Nishimori, I, Sugimoto, T, et al. The benefit of the supplementation of perioperative branched-chain amino acids in patients with surgical management for hepatocellular carcinoma: a preliminary study. Dig Dis Sci 2007 May 18; [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/46\">",
"      Morlion BJ, Stehle P, Wachtler P, et al. Total parenteral nutrition with glutamine dipeptide after major abdominal surgery: a randomized, double-blind, controlled study. Ann Surg 1998; 227:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/47\">",
"      Powell-Tuck J, Jamieson CP, Bettany GE, et al. A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition. Gut 1999; 45:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6664/abstract/48\">",
"      Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med 2008; 34:1980.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2880 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6664=[""].join("\n");
var outline_f6_32_6664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONSEQUENCES OF MALNUTRITION IN SURGICAL PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUTRITIONAL ASSESSMENT IN THE SURGICAL PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NUTRITIONAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OUTCOMES WITH NUTRITIONAL INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Parenteral feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Enteral feeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Immunonutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10165566\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2880\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2880|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12351\" title=\"figure 1\">",
"      Nomogram for BMI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2880|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/19/1341\" title=\"table 1\">",
"      Signs of nutritional deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44152?source=related_link\">",
"      Nutrition and dietary interventions in adults with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7561?source=related_link\">",
"      Secondary immune deficiency due to miscellaneous causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/4/29770?source=related_link\">",
"      The role of parenteral and enteral/oral nutritional support in patients with cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6665="Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring";
var content_f6_32_6665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Jennifer Ang Chan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Matthew Kulke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6665/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/32/6665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine cells are distributed widely throughout the body, and neoplasms of these dispersed cells can arise at many sites. While there are differences in terminology and grading for these tumors arising at different sites, all commonly used classification systems reflect a basic separation between more indolent, well differentiated tumors (which in the digestive system have been traditionally referred to as carcinoids or pancreatic neuroendocrine [islet cell] tumors) and far more aggressive poorly differentiated types that behave clinically more like small cell carcinoma of the lung. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical presentation, prognosis, radiographic imaging, and tumor marker evaluation of patients with advanced or metastatic neuroendocrine tumors (NETs) arising in the digestive system are discussed in this topic review. Pathology and nomenclature of gastroenteropancreatic NETs, treatment options for advanced or metastatic NETs, as well as issues relating to the presentation, localization, and treatment of early stage carcinoids and pancreatic islet cell tumors are presented elsewhere, as is small cell lung cancer and neuroendocrine carcinoma of unknown primary site.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"       \"Clinical characteristics of carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"       \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"       \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"       \"Insulinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link\">",
"       \"Glucagonoma and the glucagonoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"       \"Somatostatinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262522852\">",
"    <span class=\"h1\">",
"     CLASSIFICATION AND NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 World Health Organization (WHO) classification of neuroendocrine tumors arising in the digestive system (gastroenteropancreatic NETs) separates these tumors into two broad categories [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated neuroendocrine tumors, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. These tumors have been traditionally referred to as carcinoids when arising in the tubular gastrointestinal tract, or pancreatic neuroendocrine (islet cell) tumors.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung (",
"      <a class=\"graphic graphic_picture graphicRef74630 \" href=\"UTD.htm?26/10/26794\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poorly differentiated neuroendocrine carcinomas are often associated with a rapid clinical course; as such, their clinical behavior is similar to that of small cell carcinoma of the lung, and they are treated similarly with platinum-based chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, well-differentiated neuroendocrine tumors of the digestive system generally have a much better prognosis. However, these tumors are not a homogeneous group, but instead display a spectrum of aggressiveness. Even in the presence of liver metastases, some patients may survive for many years.",
"   </p>",
"   <p>",
"    Within the subgroup of well-differentiated NETs, morphology alone cannot predict tumor behavior. Proliferative rate, as assessed by mitotic count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Ki67 labeling index, is of prognostic significance, independent of tumor stage. The WHO classification separates well-differentiated gastroenteropancreatic NETs into low-grade (G1) and intermediate grade (G2) categories based upon proliferative rate (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/1\">",
"     1",
"    </a>",
"    ]. All poorly differentiated neuroendocrine tumors are high-grade (G3) neuroendocrine carcinomas according to this classification scheme. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H799311#H799311\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Functionality also impacts on nomenclature. Functioning NETs are defined based upon the presence of clinical symptoms due to excess hormone secretion by the tumor. Functioning (hormone-secreting) pancreatic NETs are classified according to the predominant hormone they secrete and the resulting clinical syndrome (eg, insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma); functioning carcinoids (ie, those associated with the carcinoid syndrome) are not classified any differently than nonfunctioning tumors. Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functioning NETs is defined by the grade and stage of the tumor, just as it is in non-functioning tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link\">",
"     \"Glucagonoma and the glucagonoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"     \"Somatostatinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H799428#H799428\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Functionality and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical course of patients with metastatic NET is highly variable. Some untreated patients with indolent tumors remain symptom-free for years, while others have symptomatic disease, either from tumor bulk or peptide hormone hypersecretion. Patients with functioning pancreatic NETs typically have symptoms caused by the specific type of hormone being produced by the tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link&amp;anchor=H4#H4\">",
"     \"Glucagonoma and the glucagonoma syndrome\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H6#H6\">",
"     \"Insulinoma\", section on 'Symptoms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link&amp;anchor=H2#H2\">",
"     \"Somatostatinoma\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link&amp;anchor=H3#H3\">",
"     \"The VIPoma syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With metastatic carcinoids, the secretion of serotonin and other vasoactive substances causes carcinoid syndrome, which is manifested by episodic flushing, wheezing, diarrhea, and eventual right-sided valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/3\">",
"     3",
"    </a>",
"    ]. The carcinoid syndrome is most commonly seen with midgut carcinoid tumors (small intestine, appendix, proximal large bowel), almost exclusively in the setting of metastatic (usually liver) disease. It is rare with foregut (gastric, bronchial) and hindgut (distal colon, rectum, genitourinary) carcinoids. Patients with extraintestinal (eg, ovarian and bronchial) carcinoids can develop carcinoid syndrome in the absence of liver metastases (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262522922\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival times for patients with advanced NET are generally better than those for patients with other malignancies, although highly variable. In a study from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) database, the median survival for patients with distant metastases from pancreatic NETs was two years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/4\">",
"     4",
"    </a>",
"    ], whereas in a large institutional database, the median survival for similar patients was 5.8 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among carcinoid tumors, prognosis may vary depending on a number of factors, including site of origin. In one institutional series, the reported median survival was 12.5 years for patients with advanced small bowel carcinoid; the corresponding survival for other carcinoids was 4.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/6\">",
"     6",
"    </a>",
"    ]. Similarly, in the SEER database report, the median survival among patients with distant metastases from carcinoid was 56 months for small bowel primaries, compared to 5 and 27 months for colon and appendiceal primaries, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/4\">",
"     4",
"    </a>",
"    ]. Differences in reported survival times in population-based and institutional series likely reflect variability in tumor classification, patient selection, and reporting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant site of metastatic spread for both carcinoids and pancreatic NETs is the liver (",
"    <a class=\"graphic graphic_picture graphicRef61729 \" href=\"UTD.htm?40/51/41777\">",
"     picture 2",
"    </a>",
"    ). Liver function tests are an unreliable indicator of tumor involvement; the serum alkaline phosphatase is frequently normal despite extensive liver involvement. Imaging is therefore an important aspect of monitoring patients with advanced gastroenteropancreatic NETs for evidence of disease progression or treatment response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21668993\">",
"    <span class=\"h2\">",
"     Well-differentiated NETs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262522974\">",
"    <span class=\"h3\">",
"     Cross-sectional imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-sectional anatomic imaging remains the standard approach to monitoring patients with advanced carcinoid and pancreatic NETs, and is generally performed with either multi-phasic CT or MRI. Triphasic helical CT of the abdomen and pelvis is recommended to image metastatic carcinoid and pancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These tumors are highly vascular and may appear isodense with the liver during certain contrast phases (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52935 \" href=\"UTD.htm?16/0/16392\">",
"     image 1",
"    </a>",
"    ). They generally enhance most intensely with intravenous contrast during the early arterial phases of imaging, with washout during the delayed portal venous phase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=see_link&amp;anchor=H5#H5\">",
"     \"Computed tomography of the hepatobiliary tract\", section on 'Helical (spiral) CT'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is a reasonable alternative, as lesions can be visualized without contrast in T1 and T2-weighted sequences, reducing the variability sometimes seen with CT-based imaging results (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59487 \" href=\"UTD.htm?10/32/10754\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72303 \" href=\"UTD.htm?17/15/17654\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In one study, MRI detected significantly more metastases than either planar somatostatin receptor scintigraphy (SRS, OctreoScan) or CT (sensitivity rates for MRI, planar SRS and CT were 95, 79, and 49 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result of this greater sensitivity for liver metastases, some physicians prefer MRI over CT. Consensus-based guidelines from the European Neuroendocrine Tumor Society (ENETS) state that MRI should be considered superior to CT for the detection and follow-up of liver metastases from NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Somatostatin receptor scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of gastroenteropancreatic NETs, including non-functioning islet cell tumors and carcinoids, have high concentrations of somatostatin receptors, and can be imaged using a radiolabeled form of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (indium-111 [111-In] pentetreotide, OctreoScan) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. In older studies, somatostatin receptor scintigraphy (SRS) was reportedly more sensitive than CT for detection of metastatic disease; SRS has also been used to help provide information regarding primary tumor location (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62072 \" href=\"UTD.htm?41/44/42703\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In light of more recent improvements in cross-sectional imaging, the clinical value of SRS in the routine follow up of patients with advanced NET (both for primary tumor localization and detection of metastatic disease) has been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/17\">",
"     17",
"    </a>",
"    ]. However, baseline SRS may still be useful as the uptake of radiolabeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    is predictive of a clinical response to therapy with somatostatin analogs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/18\">",
"     18",
"    </a>",
"    ]. Consensus-based guidelines from the European Neuroendocrine Tumor Society (ENETS) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/13,19\">",
"     13,19",
"    </a>",
"    ] and others [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/20\">",
"     20",
"    </a>",
"    ] suggest SRS for assessing secondary sites of disease involvement. Guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest use of SRS &ldquo;as appropriate&rdquo;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link&amp;anchor=H12145128#H12145128\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\", section on 'Somatostatin-receptor scintigraphy (OctreoScan)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948921#H190948921\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Somatostatin analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients receiving treatment with somatostatin analogs, when clinically feasible, therapy with short-acting analogs should be discontinued for 24 hours before SRS, and treatment can be resumed the day after [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/21\">",
"     21",
"    </a>",
"    ]. Long-acting preparations (Sandostatin LAR,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"     lanreotide",
"    </a>",
"    ) should preferably be stopped five to six weeks before the study, and patients should be switched to short-acting formulations up to one day before the study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other functional imaging methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not yet widely available, several positron emission tomography (PET) tracers for functional imaging have emerged (18-F-dihydroxy-phenyl-alanine [18F-DOPA], 11-C-5-hydroxytryptophan [11-C-5-HTP], and 68-Ga-DOTA-D-Phe",
"    <sup>",
"     1",
"    </sup>",
"    -Tyr",
"    <sup>",
"     3",
"    </sup>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    [68-Ga-DOTATOC]), which, in combination with high resolution PET and integrated CT, hold promise for improved detection and staging of NETs in the future (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81388 \" href=\"UTD.htm?15/21/15703\">",
"     image 5",
"    </a>",
"    ). These novel PET modalities offer higher spatial resolution than conventional somatostatin receptor scintigraphy (SRS) and are associated with improved sensitivity for detection of small lesions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of patients with carcinoid (n = 24) or pancreatic NET (n = 23) who had at least one lesion on conventional imaging, integrated",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      imaging with 18F-DOPA had a diagnostic sensitivity of 98 percent for carcinoid tumors, compared to 49, 73, and 63 percent for SRS,",
"      <span class=\"nowrap\">",
"       SRS/CT",
"      </span>",
"      and CT alone, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/22\">",
"       22",
"      </a>",
"      ]. Among patients pancreatic NETs, the diagnostic sensitivity of",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      using 11-C-5-HTP was 96 percent, compared to 46, 77, and 68 percent for SRS,",
"      <span class=\"nowrap\">",
"       SRS/CT",
"      </span>",
"      and CT alone, respectively.",
"     </li>",
"     <li>",
"      Another study of 68-Ga-DOTATOC PET compared to OctreoScan SPECT imaging in 27 patients with NET demonstrated superior sensitivity of PET imaging for detection of tumors in the bone and lungs [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whereas some guidelines suggest that functional imaging with one of these tracers is preferred over conventional SRS, where available [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/20\">",
"     20",
"    </a>",
"    ], others recommend against their use in the standard workup of a neuroendocrine tumor unless SRS is negative [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21669032\">",
"    <span class=\"h2\">",
"     Poorly differentiated neuroendocrine carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor staging for poorly differentiated neuroendocrine carcinomas (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) requires CT of the chest, abdomen, and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/13\">",
"     13",
"    </a>",
"    ]. The value of SRS of functional PET imaging in this setting is unclear, and these tests are not generally recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H2474956#H2474956\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on '2010 WHO classification'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Urinary 5-HIAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing carcinoid tumors (ie, those arising in the midgut), but they are not particularly sensitive. In one study, only 73 percent of patients with metastatic carcinoid tumors had elevated levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/24\">",
"     24",
"    </a>",
"    ]. Furthermore, 5-HIAA levels are generally most useful in patients with primary midgut carcinoid tumors. Foregut and hindgut carcinoids only rarely secrete serotonin; they lack the enzyme DOPA decarboxylase, and cannot convert 5-hydroxytryptophan (5-HT) to serotonin, and therefore, to 5-HIAA (",
"    <a class=\"graphic graphic_figure graphicRef51368 \" href=\"UTD.htm?12/15/12542\">",
"     figure 1",
"    </a>",
"    ). Urinary serotonin levels may be a more reliable marker for these carcinoids. This is because when 5-HT is released into the systemic circulation, DOPA decarboxylase in the renal parenchyma converts it to serotonin, leading to high urinary levels of serotonin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\", section on 'Biochemical testing for the carcinoid syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical utility can also be limited by false positives. The normal rate of 5-HIAA excretion ranges from 2 to 8 mg (10 to 42 micromol) per day. Values of up to 30 mg (157 micromol) per day may be found in patients with malabsorption syndromes (eg, celiac disease), and following ingestion of large amounts of",
"    <span class=\"nowrap\">",
"     tryptophan/serotonin-rich",
"    </span>",
"    foods; use of certain drugs also interferes with assay of urinary 5-HIAA (",
"    <a class=\"graphic graphic_table graphicRef79968 \" href=\"UTD.htm?7/54/8043\">",
"     table 3",
"    </a>",
"    ). Although most patients with advanced carcinoid tumors have values above 100 mg (523 micromol) per day, some have more modest elevations. In one study, urinary 5-HIAA excretion in patients with carcinoid syndrome ranged from 99 to 2070 mg (518 to 10826 micromol) per day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/26\">",
"     26",
"    </a>",
"    ]. Lower but still elevated values were seen in patients with metastatic carcinoid without carcinoid syndrome (50 to 260 mg [262 to 1360 micromol] per day).",
"   </p>",
"   <p>",
"    Serial measurements of 24-hour urine 5-HIAA also do not correlate with symptomatic benefit from various treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/27\">",
"     27",
"    </a>",
"    ]. For all of these reasons, and the inconvenience of collecting 24-hour urine samples, chromogranin A is the preferred biomarker for monitoring disease activity among patients with advanced gastroenteropancreatic NETs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716132\">",
"    <span class=\"h2\">",
"     Functioning pancreatic NETs",
"    </span>",
"    &nbsp;&mdash;&nbsp;While they are specific for the individual hormonal syndrome, the hormones produced by functioning pancreatic NETs (ie, insulin, glucagon, somatostatin, VIP) are not always easily measurable. Other markers, such as chromogranin A, may be more useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H9#H9\">",
"     \"Insulinoma\", section on 'Diagnosis and staging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucagonoma and the glucagonoma syndrome\", section on 'Serum glucagon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\", section on 'Serum gastrin concentration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link&amp;anchor=H390935#H390935\">",
"     \"The VIPoma syndrome\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link&amp;anchor=H3#H3\">",
"     \"Somatostatinoma\", section on 'Diagnosis, localization, and staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chromogranin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromogranin A (CgA) is a 49-kD protein that is contained in the neurosecretory vesicles of neuroendocrine tumor cells and is detectable in the plasma of patients with a range of neuroendocrine neoplasms, including nonfunctioning pancreatic NETs. Because it does not rely on serotonin secretion, serum CgA is a more sensitive and broadly applicable tumor marker for NETs than is urinary 5HIAA, but it is less specific (",
"    <a class=\"graphic graphic_table graphicRef73287 \" href=\"UTD.htm?40/9/41116\">",
"     table 4",
"    </a>",
"    ). CgA may be used in patients with bronchial and rectal carcinoid tumors (in whom urinary 5HIAA levels are less likely to be elevated), as well as in patients with pancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/28-37\">",
"     28-37",
"    </a>",
"    ]. Levels are higher in patients with diffuse metastases than with localized disease or isolated hepatic involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Foregut tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Hindgut tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma CgA levels have been shown to correlate with treatment response and may also have prognostic value. Elevated CgA levels have been associated with shorter overall survival times in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. However, the utility of CgA as a marker of prognosis has been limited by wide variability in CgA ranges in the setting of metastatic disease, as well as variability in CgA assays in the US and Europe. Caution is also needed when using serum CGA as a marker of disease activity in patients treated with somatostatin analogs. These agents significantly reduce plasma CgA levels, a change that may be more reflective of changes in hormonal synthesis and release from tumor cells than an actual reduction in tumor mass [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/31\">",
"     31",
"    </a>",
"    ]. Finally, CgA is not recommended as a diagnostic marker for NETs, as it can be elevated in a number of unrelated conditions. These conditions include use of proton pump inhibitors, renal insufficiency, and hepatic insufficiency. For patients who are receiving treatment with a proton pump inhibitor, the drug should be stopped or replaced with an H2 receptor blocker if possible in order to obtain reliable CgA values [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other serum markers, such as alfa-fetoprotein and human chorionic gonadotropin, are elevated in some patients with NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/42\">",
"     42",
"    </a>",
"    ], but their clinical utility over CGA alone has not been demonstrated.",
"   </p>",
"   <p>",
"    Preliminary data suggest that elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with the presence and severity of tricuspid regurgitation (TR) as a manifestation of carcinoid heart disease among patients with neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6665/abstract/40\">",
"     40",
"    </a>",
"    ]. We do not at this time advocate routine screening with NT-proBNP, since echocardiography remains the standard for detection and quantitation of TR in patients with carcinoid disease. Most clinicians recommend a baseline echocardiogram in all patients with the carcinoid syndrome, and in those who develop clinical features of right heart failure, if valve replacement would be an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link&amp;anchor=H11#H11\">",
"     \"Carcinoid heart disease\", section on 'Biomarkers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroendocrine tumors (NETs) arising at different sites within the body are classified according to their histologic features. All commonly used classification systems reflect a basic separation between more indolent, well differentiated tumors (traditionally referred to as carcinoids, islet cell, or pancreatic NETs), and far more aggressive poorly differentiated types that behave clinically more like small cell neuroendocrine tumors. (See",
"      <a class=\"local\" href=\"#H262522852\">",
"       'Classification and nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course of patients with metastatic carcinoid and pancreatic NETs is highly variable. Some patients with indolent tumors may remain symptom-free for years, even without treatment. Others have symptomatic metastatic disease, either from tumor bulk or peptide hormone hypersecretion, and require therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant site of metastatic spread is the liver. Patients in whom metastatic disease is suspected should be evaluated with a triple-phase contrast-enhanced helical CT or an MRI scan to rule out liver metastases. Some physicians prefer MRI because of its greater sensitivity for liver metastases.",
"     </li>",
"     <li>",
"      The clinical value of SRS in the routine follow up of patients with advanced NET has been called into question. Baseline SRS may still be useful, however, as the uptake of radiolabeled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      is predictive of a clinical response to therapy with somatostatin analogs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Changes in biochemical markers may be associated with disease progression",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      response to treatment. Elevated urinary levels of 5-hydroxyindoleacetic acid (5-HIAA) are highly specific for serotonin-producing carcinoid tumors (ie, those arising in the midgut), although they are not sensitive. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Urinary 5-HIAA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For non-serotonin producing carcinoids and pancreatic neuroendocrine tumors, serum chromogranin A (CGA) is a more sensitive than 5-HIAA, though serum levels of CGA can also be elevated in non-neuroendocrine related conditions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chromogranin A'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/2\">",
"      Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/3\">",
"      THORSON A, BIORCK G, BJORKMAN G, WALDENSTROM J. Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome. Am Heart J 1954; 47:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/4\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/5\">",
"      Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas 2009; 38:255.",
"     </a>",
"    </li>",
"    <li>",
"     Ter-Minassian, M, Frauenhoffer, CS, Hooshmand, SM, et al. Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs). (abstract #4044). J Clin Oncol 2010; 28:311s. (Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=43584 (Accessed on February 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/7\">",
"      Woodard PK, Feldman JM, Paine SS, Baker ME. Midgut carcinoid tumors: CT findings and biochemical profiles. J Comput Assist Tomogr 1995; 19:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/8\">",
"      Sugimoto E, L&ouml;relius LE, Eriksson B, Oberg K. Midgut carcinoid tumours. CT appearance. Acta Radiol 1995; 36:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/9\">",
"      Woodside KJ, Townsend CM Jr, Mark Evers B. Current management of gastrointestinal carcinoid tumors. J Gastrointest Surg 2004; 8:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/10\">",
"      Warner RR, Mani S, Profeta J, Grunstein E. Octreotide treatment of carcinoid hypertensive crisis. Mt Sinai J Med 1994; 61:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/11\">",
"      Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005; 23:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/12\">",
"      Sundin A, Vullierme MP, Kaltsas G, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/13\">",
"      Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/14\">",
"      Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 1990; 323:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/15\">",
"      Kvols LK, Brown ML, O'Connor MK, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993; 187:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/16\">",
"      Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/17\">",
"      Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/18\">",
"      Hillman N, Herranz L, Alvarez C, et al. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998; 106:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/19\">",
"      Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/20\">",
"      Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/21\">",
"      Kwekkeboom DJ, Krenning EP, Scheidhauer K, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009; 90:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/22\">",
"      Koopmans KP, Neels OC, Kema IP, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008; 26:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/23\">",
"      Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/24\">",
"      Feldman JM, O'Dorisio TM. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 1986; 81:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/25\">",
"      Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 2000; 232:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/26\">",
"      Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/27\">",
"      Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001; 25:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/28\">",
"      Seregni E, Ferrari L, Bajetta E, et al. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol 2001; 12 Suppl 2:S69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/29\">",
"      Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/30\">",
"      Stivanello M, Berruti A, Torta M, et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann Oncol 2001; 12 Suppl 2:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/31\">",
"      Oberg K. Management of neuroendocrine tumours. Ann Oncol 2004; 15 Suppl 4:iv293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/32\">",
"      Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/33\">",
"      Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/34\">",
"      Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/35\">",
"      Giovanella L, La Rosa S, Ceriani L, et al. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings. Int J Biol Markers 1999; 14:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/36\">",
"      Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth 2001; 87:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/37\">",
"      Veall GR, Peacock JE, Bax ND, Reilly CS. Review of the anaesthetic management of 21 patients undergoing laparotomy for carcinoid syndrome. Br J Anaesth 1994; 72:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/38\">",
"      Arnold R, Wilke A, Rinke A, et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008; 6:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/39\">",
"      Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997; 8:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/40\">",
"      Korse CM, Taal BG, de Groot CA, et al. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol 2009; 27:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/41\">",
"      Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 105:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6665/abstract/42\">",
"      Shah T, Srirajaskanthan R, Bhogal M, et al. Alpha-fetoprotein and human chorionic gonadotrophin-beta as prognostic markers in neuroendocrine tumour patients. Br J Cancer 2008; 99:72.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2194 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-F7344C3B4D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6665=[""].join("\n");
var outline_f6_32_6665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H46\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262522852\">",
"      CLASSIFICATION AND NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H262522922\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21668993\">",
"      Well-differentiated NETs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262522974\">",
"      - Cross-sectional imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other functional imaging methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21669032\">",
"      Poorly differentiated neuroendocrine carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BIOCHEMICAL MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Urinary 5-HIAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11716132\">",
"      Functioning pancreatic NETs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chromogranin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2194|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/0/16392\" title=\"diagnostic image 1\">",
"      CT neuroendocrine tumor liver metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/32/10754\" title=\"diagnostic image 2\">",
"      MRI pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/15/17654\" title=\"diagnostic image 3\">",
"      T2 MRI well differentiated pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/44/42703\" title=\"diagnostic image 4\">",
"      Primary ileal NET somatostatin receptor scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/21/15703\" title=\"diagnostic image 5\">",
"      Functional PET imaging for metastatic GI neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2194|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/15/12542\" title=\"figure 1\">",
"      Tryptophan and serotonin metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2194|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/10/26794\" title=\"picture 1\">",
"      Histologic appearance of neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/51/41777\" title=\"picture 2\">",
"      Hepatic metastases GI neuroendocrine tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17644\" title=\"table 1\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 2\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/54/8043\" title=\"table 3\">",
"      Interference with 5 HIAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/9/41116\" title=\"table 4\">",
"      Conditions associated with elevated chromogranin A",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18950?source=related_link\">",
"      Computed tomography of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6666="Treatment of acute graft-versus-host disease: Clinical trials";
var content_f6_32_6666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute graft-versus-host disease: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/32/6666/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/32/6666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically significant acute graft-versus-host disease (GVHD) occurs in 9 to 50 percent of patients who receive an allogeneic hematopoietic cell transplant from a genotypically HLA-identical sibling, despite intensive prophylaxis with immunosuppressive agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , corticosteroids, or antithymocyte globulin. Acute GVHD is more common in matched unrelated donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids are the first-line therapy for patients who fail prophylaxis (usually with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) and develop acute GVHD. Other modalities that have been used to treat acute GVHD include antithymocyte globulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , monoclonal antibodies, and extracorporeal photochemotherapy.",
"   </p>",
"   <p>",
"    The clinical trials that have evaluated these modalities for the treatment of acute GVHD will be reviewed here. Specific recommendations for the prevention and treatment of acute GVHD and for treatment of chronic GVHD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"     \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link\">",
"     \"Treatment of chronic graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which glucocorticoids act in reversing acute GVHD is incompletely understood. It had been assumed that their lympholytic activity was of primary importance but they also diminish the release of cytokines that are thought to be associated with GVHD, including interleukin (IL)-1, IL-2, IL-6, interferon-gamma, and tumor necrosis factor-alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used corticosteroid is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , which differs from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    only by the addition of 6-alpha-methyl group. This methyl group blocks specific binding of methylprednisolone to cortisol-binding globulin (CBG, transcortin) to which cortisol and most other synthetic glucocorticoids bind; instead, methylprednisolone is primarily bound to albumin. As a result, the frequency of side effects from methylprednisolone may be dependent upon the albumin level in the host.",
"   </p>",
"   <p>",
"    A variety of different glucocorticoid regimens have been evaluated. An initial study used high-dose intravenous bolus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for three days followed by a taper [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/4\">",
"     4",
"    </a>",
"    ]. This regimen produced a prompt complete or partial response in 93 percent of patients, but recrudescence was observed with dose reduction.",
"   </p>",
"   <p>",
"    Another protocol consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    given at a dose of as much as 500",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    every six hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/5\">",
"     5",
"    </a>",
"    ]. Although initially effective for skin and gut manifestations, there was an incomplete and slow response of the liver disease and all of the long-term survivors developed chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of the failures from these two regimens were due to opportunistic infection or interstitial pneumonitis.",
"   </p>",
"   <p>",
"    A more moderate dose increase to 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent has also been evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with mild to moderate GVHD had an excellent response, but those with severe GVHD did poorly. Successful therapy of acute GVHD does not affect the risk of leukemic relapse in patients transplanted for this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to compare these different approaches, a multicenter trial randomized 95 patients with acute GVHD to early treatment with low (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/8\">",
"     8",
"    </a>",
"    ]. On day 5 of therapy, almost one-half of patients in the low dose group were switched to a higher dose because of lack of response or progression. With this strategy, there were no differences in mean response rates or actuarial survival at three years (63 versus 62 percent).",
"   </p>",
"   <p>",
"    These data suggest that starting with low dose steroids may be an appropriate regimen. Day 5 responders can then proceed with tapering doses and nonresponders would be eligible for high dose steroids or alternative immunosuppressive regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=see_link&amp;anchor=H164641640#H164641640\">",
"     \"Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease\", section on 'Clinical use and toxicities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Beclomethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral beclomethasone in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    may be more effective than prednisone alone in treating intestinal GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized study, 60 patients with anorexia and poor oral intake because of intestinal GVHD were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) plus either placebo or oral beclomethasone (8",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/9\">",
"       9",
"      </a>",
"      ]. Beclomethasone therapy was associated with a higher likelihood of both an initial treatment response at day 10 (71 versus 55 percent) and a durable treatment response at day 30 (71 versus 41 percent).",
"     </li>",
"     <li>",
"      In a second trial, 129 patients were treated for 10 days with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (with tapering after 10 days) and then randomly assigned to receive either placebo or oral beclomethasone (8",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      PO) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/10\">",
"       10",
"      </a>",
"      ]. On an intent-to-treat basis, the risk of GVHD-treatment failure was significantly reduced in the group receiving beclomethasone, along with a 67 percent reduction in the hazard for mortality for all patients and a 91 percent mortality reduction for patients receiving unrelated and HLA-mismatched transplants. This study did not meet the primary endpoint. A third study was initiated but stopped early due to lack of efficacy. At this time it is difficult to conclude that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      adds much to the treatment of GVHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTITHYMOCYTE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary role of T cells in the pathogenesis of GVHD provides the rationale for the use of antithymocyte globulin (ATG) and other anti-T cell antibodies. An initial report from Seattle evaluated the efficacy of ATG among 60 patients with grade II GVHD: 36 improved, 12 did not improve, and 12 had progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/11\">",
"     11",
"    </a>",
"    ]. These observations provided the rationale for a subsequent randomized trial which compared ATG (given on alternate days for six doses) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 10 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/12\">",
"     12",
"    </a>",
"    ]. More responses were seen in the steroid group although the difference was not significant. All organ systems appeared to respond to steroid therapy whereas ATG produced only a few, incomplete responses in the gastrointestinal tract and liver.",
"   </p>",
"   <p>",
"    Another study investigated the combination of ATG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ; some of the patients also received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients receiving triple therapy had a lower survival rate, mostly due to infectious complications. Untoward effects of ATG included hemolytic anemia, severe thrombocytopenia, neutropenia, fever, chills, polyarthritis, myalgias, nausea, vomiting, urticaria, and serum sickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TACROLIMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are closely related, several anecdotal reports suggest that tacrolimus may be used to treat patients who have failed prophylaxis with cyclosporine. Currently, however, these are only case reports and abstracts; there are no prospective studies to suggest the actual salvage rate with tacrolimus for those who have failed prophylaxis with cyclosporine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MONOCLONAL ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoclonal antibodies directed against T cells, activated T cells, the interleukin-2 receptor (CD25 antigen), adhesion molecules, and tumor necrosis factor-alpha have been evaluated in the treatment of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/14\">",
"     14",
"    </a>",
"    ]. The usefulness of these antibodies can be difficult to assess due to a number of factors. In almost all trials, the antibodies were used as second line therapy in patients who did not respond to steroids and already had full-blown acute GVHD. In addition, monoclonal antibodies are selective, acting on specific sites in the immunologic cascade, and it may be that combination therapy at an earlier stage will provide superior results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     OKT3 and anti-CD3 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monoclonal antibody OKT3, which is directed against the CD3 antigen that is closely associated with the T cell receptor, was first shown to be effective in the treatment of acute rejection in renal transplant recipients. It has also been evaluated for the treatment of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A pilot trial in eight allogeneic recipients with grade II to IV acute GVHD showed a response in six, especially those with very minimal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/15\">",
"     15",
"    </a>",
"    ]. A second study evaluated 10 patients with grade III-IV acute GVHD which was resistant to cyclosporine and methylprednisolone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/16\">",
"     16",
"    </a>",
"    ]. OKT3 induced complete responses in five and partial responses in four patients, but recurrent GVHD was common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=see_link\">",
"     \"Acute renal allograft rejection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the long-term efficacy of OKT3 in the treatment of acute GVHD has not been established. Furthermore, the dose-limiting side effects resulting from T cell activation and the high incidence of infection (42 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/17\">",
"     17",
"    </a>",
"    ] have discouraged further use of this antibody.",
"   </p>",
"   <p>",
"    Unfortunately, the use of OKT3 or anti-CD3 monoclonal antibodies has resulted in development of the posttransplant lymphoproliferative syndrome from polyclonal and, in some cases, monoclonal proliferation of B cells infected with the Epstein-Barr virus. The optimal treatment of this additional complication is uncertain; novel therapies such as the concomitant use of anti-B cell antibodies (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    ) have been promising in initial studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anti-CD3 and anti-CD5 immunotoxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;An extension of the anti-CD3 antibody approach is the creation of a fusion immunotoxin in which the antibody is fused to a truncated from of diphtheria toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/18\">",
"     18",
"    </a>",
"    ]. In a rat model of GVHD, 80-day survival was markedly increased in rats given the immunotoxin compared with controls given the truncated toxin alone (86 versus 43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another immunotoxin, H65-RTA, is a CD5-specific antibody conjugated to ricin A, a potent inhibitor of protein synthesis. CD5 antigen is present on almost 95 percent of peripheral blood lymphocytes and in a small number of normal B lymphocytes. As a result, H65-RTA forms a complex that is specifically toxic for T lymphocytes. The efficacy of this toxin, which is not yet commercially available, was evaluated in a randomized double blind trial in which initial therapy of 243 patients with acute GVHD consisted of standard steroid therapy plus either the toxin or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/20\">",
"     20",
"    </a>",
"    ]. The combined regimen of H65-RTA and steroids was more effective than steroids alone during the first five weeks after starting treatment but there was no difference between the two groups in survival at one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anti-interleukin-2 receptor antibodies (daclizumab)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different approach to the treatment of steroid-resistant grade II-IV acute GVHD is the administration of monoclonal antibodies directed against the IL-2 receptor (B-B10, anti-CD25). In one series of 23 patients, the antibody was given at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 10 days and then 5 mg every other day for another 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/21\">",
"     21",
"    </a>",
"    ]. Antibody administration was associated with an 84 percent response rate (65 percent complete and 19 percent partial); responses appeared more likely with early treatment.",
"   </p>",
"   <p>",
"    These promising initial results were followed by a multicenter pilot study in which 32 patients with steroid-resistant acute GVHD were treated with the anti IL-2 receptor antibody (initially named B-B10 and later renamed BT 563) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/22\">",
"     22",
"    </a>",
"    ]. A full response of organ involvement was achieved in 69 percent. Although this report did not state whether the responses were durable, a follow-up study of 58 patients found that 45 percent were alive between 240 and 900 days after GVHD treatment with B-B10 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/23\">",
"     23",
"    </a>",
"    ]. There was a significant survival advantage for those patients who responded to B-B10, but the GVHD recurrence rate was 41 percent. Factors associated with a good response were a short delay between the onset of GVHD and antibody administration, the absence of liver involvement, and lower pretreatment serum soluble CD8 antigen levels. In another report, both lower serum soluble CD8 and serum tumor necrosis factor-alpha levels were associated with a better response to B-B10 in patients with steroid-resistant GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Murine monoclonal antibodies have immunogenic potential and can lead to the production of antimurine antibodies that can reduce therapeutic efficacy by eliminating the antibody from the body more quickly. To reduce this potential, chimeric monoclonal antibodies consisting of human constant regions and mouse variable regions have been developed. Humanized anti-Tac (HAT) is a genetically engineered humanized IgG1 monoclonal antibody specific for Tac, the alpha subunit of the interleukin-2 receptor. A phase I-II study of 20 patients with steroid-resistant GVHD suggested that it was less immunogenic and had more favorable pharmacokinetics than the murine antibody but the overall rate of improvement was only 40 percent, with mean survival of 76 days [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improved results have been observed in a second study that examined the efficacy of a multidose strategy utilizing this antibody, now known as daclizumab, in two cohorts of patients with severe or steroid-resistant acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/26\">",
"     26",
"    </a>",
"    ]. In the second cohort of 19 patients, treatment with 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of daclizumab on days 1, 4, 8, 15, and 22 resulted in a complete response in nearly one-half of patients by day 43, with 53 percent survival at day 120. In an additional study which used the same dose and schedule of daclizumab, complete resolution of acute GVHD was achieved in 69 percent, with higher response rates in those with fewer involved organs and less extensive skin involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/27\">",
"     27",
"    </a>",
"    ]. Unfortunately, most of the patients went on to develop extensive chronic GVHD.",
"   </p>",
"   <p>",
"    A combined approach using this agent was successfully utilized in patients with steroid-resistant acute GVHD following nonmyeloablative HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/28\">",
"     28",
"    </a>",
"    ]. In this study, 12 patients were treated with daclizumab (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV on days 1, 4, 8, 15, and 22), alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV on days 1, 8, 15, and 22). Additional treatment to reduce the incidence of infection included IV lipid formulation amphotericin concurrent with a rapid tapering of corticosteroids, prophylactic",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"     /sulbactam",
"    </span>",
"    for grades III-IV gastrointestinal involvement, and continued treatment with IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil. GVHD-related mortality at 200 days was 17 percent for this regimen versus 89 percent for a prior group of 12 similar patients treated with ATG and MMF alone.",
"   </p>",
"   <p>",
"    Based on these encouraging results in treating patients with steroid-resistant acute GVHD, a double-blinded randomized trial was initiated to determine whether addition of daclizumab to initial corticosteroid therapy for acute GVHD improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/29\">",
"     29",
"    </a>",
"    ]. This study was terminated when an interim analysis showed significantly worse survival at both 100 days and one year for those subjects receiving the combined therapy. With data suggesting that CD25 positive T regulatory cells are important in modulating GVHD, removal of these regulatory T cells with daclizumab may have contributed to the poorer outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of graft-versus-host disease\", section on 'Regulatory T cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other IL-2 receptor monoclonal antagonists are in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    , with a shorter terminal half-life than daclizumab, was used in 23 patients with steroid-refractory acute GVHD, with an 18 percent complete and 65 percent partial response rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anti-tumor necrosis factor-alpha antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presumed contribution of tumor necrosis factor-alpha (TNFalpha) to acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/3\">",
"     3",
"    </a>",
"    ] and the association of higher serum levels with worse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/24\">",
"     24",
"    </a>",
"    ] provide the rationale for the use of anti-TNFalpha antibodies in this disorder.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter pilot trial evaluated 19 patients with severe GVHD that was refractory to both conventional therapy and anti-IL-2 receptor antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/32\">",
"       32",
"      </a>",
"      ]. There were no complete remissions but eight had a good partial response. Gut lesions responded the best, followed by skin and then liver. GVHD recurred when treatment was discontinued.",
"     </li>",
"     <li>",
"      Somewhat better results were noted in a second series in which a monoclonal anti-TNFalpha antibody termed B-C7 was given to 22 patients with grade III-IV acute GVHD. Complete and partial responses were seen in 21 and 61 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/33\">",
"       33",
"      </a>",
"      ]. However, active GVHD reappeared rapidly in eight patients and only 22 percent were alive at later follow-up.",
"     </li>",
"     <li>",
"      In a third study of 26 patients with steroid-refractory acute GVHD, complete responses were noted in 62 percent; overall survival from the time of transplantation was 31 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that anti-TNFalpha antibodies may be of benefit to some patients with severe refractory acute GVHD but are generally ineffective in preventing GVHD recurrence, and may be associated with higher rates of fungal, bacterial, and viral infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Etanercept'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with the humanized monoclonal anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (Campath) was evaluated in 20 patients with severe (grade",
"    <span class=\"nowrap\">",
"     III/IV)",
"    </span>",
"    steroid-resistant acute intestinal GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/37\">",
"     37",
"    </a>",
"    ]. Complete and overall response rates were 35 and 70 percent, respectively. Cytomegalovirus reactivation, bacterial infection, and invasive aspergillosis were frequent complications, requiring careful monitoring and anti-infectious supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other monoclonal antibodies have been evaluated in small series. These include the use of CBL1, a murine monoclonal antibody that recognizes an antigen (CD147) present on activated T lymphocytes, B lymphocytes, and natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and combination therapy with several monoclonal antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/40\">",
"     40",
"    </a>",
"    ]. The efficacy and safety of these approaches needs to be evaluated in larger studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other agents have been studied in small phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    studies to assess potential use for the treatment of acute GVHD. These include,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , photochemotherapy and anti-TNF receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil (MMF) has antibacterial, antifungal, antiviral, antitumor and immunosuppressive properties. It is currently being used to prevent rejection in organ transplantation and is being evaluated in a variety of renal and rheumatic diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An open single center trial was performed to assess efficacy and safety of MMF in the treatment of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/41\">",
"     41",
"    </a>",
"    ]. Seventeen patients with acute GVHD were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    (2000",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    . An overall grade improvement was found in 65 percent and a lower dose of prednisolone could be used. Mild leukopenia, anemia, and thrombocytopenia occurred but did not require discontinuation of therapy.",
"   </p>",
"   <p>",
"    In another prospective study of acute GVHD, 9 of 19 patients (47 percent) had a response and 10 (53 percent) had no improvement. Survival at 6 and 12 months after the start of MMF was 37 and 16 percent, respectively. In a retrospective study of acute GVHD, 14 of 29 patients (48 percent) had a response and 15 (52 percent) had no improvement. Survival at 6 and 12 months was 55 and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    has been used for the treatment of rodent models of GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In the rat, thalidomide is effective for both the prevention and treatment of GVHD. One significant disadvantage for use in humans is the erratic absorption of this drug following oral administration. Thalidomide has shown some benefit in humans with chronic GVHD but there is no reported experience in acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Extracorporeal photochemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal photochemotherapy consists of infusion of ultraviolet-A irradiated autologous peripheral lymphocytes which have been collected by apheresis and incubated with 8-methoxypsoralen. This approach appears to be effective in the treatment of cutaneous T-cell lymphoma and several autoimmune diseases and has been used to treat rejection after organ transplantation. The mechanism of its action is unclear, although it appears to downregulate activated T cell clones. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=see_link\">",
"     \"Investigational immunosuppressive drugs and approaches in clinical kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of chronic graft-versus-host disease\", section on 'Psoralen ultraviolet irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have suggested that extracorporeal photochemotherapy may have a role in the treatment of acute and chronic GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/48\">",
"     48",
"    </a>",
"    ]; both poor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/49,50\">",
"     49,50",
"    </a>",
"    ] and encouraging results have been obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In the largest study to date, 21 patients with steroid-refractory acute GVHD were treated with ECP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/53\">",
"     53",
"    </a>",
"    ]. Complete responses were noted in 100, 67, and 12 percent of patients with grades II, III, and IV acute GVHD, respectively. Probability of survival at four years was 91 and 11 percent in complete responders or non-responders to ECP, respectively.",
"   </p>",
"   <p>",
"    In a review of 11 studies employing ECP in a total of 76 patients with acute GVHD, complete responses to skin, gut, and liver involvement were noted in 67, 54, and 38 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Denileukin diftitox",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase I trial studied the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    (Ontak&reg;), a recombinant protein composed of human Interleukin-2 fused to diphtheria toxin, in 30 patients with steroid-refractory acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/55\">",
"     55",
"    </a>",
"    ]. Complete and partial remission rates were 50 and 21 percent, respectively. Hepatic transaminase elevation was the dose-limiting toxicity.",
"   </p>",
"   <p>",
"    A phase II study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    in 22 patients with steroid-resistant acute GVHD has also been reported. Twenty patients were treated at dose level 1 (4.5",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    daily on days 1 to 5 and then weekly on study days 8, 15, 22, and 29), and 2 patients were treated at dose level 2 (9.0",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    delivered on the same schedule). Dose level 2 was associated with grade",
"    <span class=\"nowrap\">",
"     3/4",
"    </span>",
"    renal and hepatic toxicity and vascular leak syndrome, and no further patients were treated at this level. Dose level 1 was generally well tolerated. The response of acute GVHD was assessed at study days 36 and 100. Nine patients (41 percent) responded, all with a complete response at study day 36, and 6 patients (27 percent) responded at study day 100 (4 complete responses and 2 partial responses) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pentostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    , a purine analog, inhibits T-cell numbers and function, and has been used to prevent GVHD in experimental animals and man. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of infectious complications following purine analog therapy\", section on 'Immunosuppression associated with purine analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A phase I trial has explored the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    in the treatment of acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/57\">",
"     57",
"    </a>",
"    ]. Complete responses were noted in 14 of 22 patients with steroid-refractory acute GVHD at a maximal tolerated dose of 1.5",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    IV per day for three days. Lymphopenia was universal; the drug was otherwise well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Etanercep (Enbrel) a recombinant human TNF-alpha receptor fusion protein, has been used alone or in combination to treat chronic and acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one set of studies, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose given SQ twice per week) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (initial dose 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) was used in 61 patients with new onset GVHD. Infection prophylaxis included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . Results, which were compared with a contemporaneous group of 99 patients treated with methylprednisolone alone, included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      plus steroids were significantly more likely to attain complete remission after 28 days than those treated with steroids alone (69 versus 33 percent). This difference was observed in HCT recipients of related donors (79 versus 39 percent) as well as unrelated donors (53 versus 26 percent).",
"     </li>",
"     <li>",
"      Plasma TNFR1 levels, a biomarker for GVHD activity, were elevated at GVHD onset and decreased significantly only in patients achieving CR.",
"     </li>",
"     <li>",
"      The higher CR rate seen in those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      translated into significantly superior survival at 100 days following initiation of treatment (82 versus 66 percent).",
"     </li>",
"     <li>",
"      Infection rates during the first 100 days of treatment for bacterial, viral, or invasive fungal infection were similar for the two treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This agent is being evaluated in a prospective, four-arm study of acute GVHD under the auspices of the BMT Clinical Trials Network (CTN). The other three agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and Ontak.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Phase II trial of available agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized phase II trial studied the relative effectiveness of the four most promising agents among those listed above, to be combined with glucocorticoids for the treatment of acute GVHD (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , denileukin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    ). Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/63\">",
"     63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Day 28 complete response rates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      , denileukin, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      were 26, 60, 53, and 38 percent, respectively.",
"     </li>",
"     <li>",
"      Nine-month overall survivals for these four treatment regimens were 47, 64, 49, and 47 percent, respectively.",
"     </li>",
"     <li>",
"      Cumulative incidences of severe infection were 48, 44, 62, and 57 percent, respectively.",
"     </li>",
"     <li>",
"      An exploratory subgroup analysis suggested that a panel of six biomarkers for GVHD measured at the initiation of therapy predicted for response to therapy and survival at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These efficacy and toxicity data suggest the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    plus glucocorticoids as the most promising regimen to compare against glucocorticoids alone in a definitive phase III trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MESENCHYMAL STEM CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow contains small numbers of mesenchymal stem cells, which are able to differentiate in vitro and in vivo into cells of mesenchymal origin (eg, fibroblasts, adipocytes, osteoblasts, chondrocytes) and are pivotal for the supply of growth factors supporting hematopoiesis. The immunosuppressive potential of these cells, including their ability to induce",
"    <span class=\"nowrap\">",
"     CD4+/CD25+/FOXP3+",
"    </span>",
"    regulatory T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/65\">",
"     65",
"    </a>",
"    ], has set the stage for their testing as cellular immunosuppressants, to promote hematopoietic recovery after autologous and allogeneic HCT, and to treat acute, severe GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/66-69\">",
"     66-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Steroid-resistant acute GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic efficacy of ex vivo-expanded mesenchymal stem cells (MSCs) was tested in 55 patients with steroid-resistant acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/69\">",
"     69",
"    </a>",
"    ]. MSCs from HLA-identical sibling donors, haploidentical donors, and third-party HLA-mismatched donors were given at a median dose of 1.4 x 10(6)",
"    <span class=\"nowrap\">",
"     cells/kg",
"    </span>",
"    for a total of one to five intravenous infusions per subject. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete and overall responses were noted in 54 and 71 percent, respectively.",
"     </li>",
"     <li>",
"      Transplantation-related mortality at one year was significantly lower (37 versus 72 percent) and overall survival at two years significantly higher (53 versus 16 percent) in those achieving complete remission as compared with those with lesser responses.",
"     </li>",
"     <li>",
"      The response rate to MSC infusion was not related to the degree of HLA matching between donor and recipient. No patient had side effects during or immediately after these infusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Use with steroids in acute GVHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II multi-institutional study evaluated the use of two different doses of third-party, unmatched mesenchymal stem cells (Prochymal, Osiris Therapeutics) in addition to standard glucocorticoid therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally daily) in 31 evaluable patients with de novo grade II-IV acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall and complete response rates were 94 and 77 percent, respectively. Of the 24 patients achieving CR, 21 (88 percent) were alive at day 90. Of the 7 patients not achieving CR, only 1 (14 percent) was alive at day 90. No infusional toxicities or ectopic tissue formations were reported. There was no difference with respect to safety or efficacy between the low and high doses of MSCs.",
"   </p>",
"   <p>",
"    A phase III trial has been completed using MSC generated by Osiris Therapeutics (Prochymal). The preliminary results which have been released to date demonstrate the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no statistical difference between MSC and placebo on the primary endpoints for either the steroid-refractory (35 versus 30 percent, n=260) or the first-line (45 versus 46 percent, n=192) GVHD trials.",
"     </li>",
"     <li>",
"      The primary endpoint for the steroid-refractory GVHD trial (durable complete response) for the per-protocol population did not reach statistical significance (40 versus 28 percent, p=0.087, n=179).",
"     </li>",
"     <li>",
"      In patients with steroid-refractory liver GVHD, treatment with MSC significantly improved both response (76 versus 47 percent, n=61) and durable complete response (29 versus 5 percent).",
"     </li>",
"     <li>",
"      MSC significantly improved response rates in patients with steroid-refractory gastrointestinal GVHD (88 versus 64 percent, n=71).",
"     </li>",
"     <li>",
"      In pediatric patients, Prochymal showed a trend of improvement in response rates (86 versus 57 percent, p=0.094, n=28).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies using this modality are ongoing at international centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATIENT OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports from Minnesota and Seattle have evaluated the outcomes in different groups of patients with acute GVHD. The Minnesota study evaluated 469 patients receiving histocompatible allogeneic hematopoietic cell transplantation, 197 of whom (42 percent) were treated for grade II-IV acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/71\">",
"     71",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-one percent achieved a complete and continued resolution of acute GVHD after a median of 21 days of therapy. Treatment in these responders consisted primarily of corticosteroids or, in a small number of patients, other immunosuppressive therapies including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , anti-T cell antibodies, or antilymphocyte globulin.",
"     </li>",
"     <li>",
"      Sixty-one patients not responding to initial therapy received high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      , ATG plus methylprednisolone, or other therapies. Only seven of these patients (11 percent) eventually obtained a complete continued remission.",
"     </li>",
"     <li>",
"      The overall rate of chronic GVHD was 70 percent; thus, 30 percent of patients were cured. In a later report from the same group, a response to primary therapy for acute GVHD was the most important factor predicting a lower risk of subsequent chronic GVHD [",
"      <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The clinical features associated with a complete response to therapy for acute GVHD included the absence of liver or skin involvement, acute lymphoblastic leukemia as the underlying disease, and",
"      <span class=\"nowrap\">",
"       donor/recipient",
"      </span>",
"      pairs other than male recipients with female donors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these results are good (30 percent cure of moderate to severe acute GVHD), many of these patients were transplanted before the availability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . GVHD prophylaxis at that time consisted predominantly of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    -based regimens either alone or in conjunction with ATG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or ex vivo T cell depletion. The more recent patients transplanted with cyclosporine-based prophylactic regimens who developed GVHD did not respond as well to the various treatments.",
"   </p>",
"   <p>",
"    The report from the Seattle group was a retrospective analysis of 427 patients who did not have a durable response to primary therapy for acute GVHD [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/73\">",
"     73",
"    </a>",
"    ]. The most common manifestations were rash (75 percent), liver disease (59 percent), and gastrointestinal dysfunction (53 percent). Secondary treatments consisted of glucocorticoids in the majority of the patients (n = 249), ATG (n = 214),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (n = 80), or a monoclonal antibody (n = 19). Most of the patients received single agent therapy. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some response to therapy was seen in 40 percent. Improvement in or resolution of GVHD in the respective organs was seen in 45 percent of patients with skin disease, 25 percent with liver disease, and 35 percent with gut disease.",
"     </li>",
"     <li>",
"      The highest complete response rate was seen when GVHD recurred during the taper phase of primary glucocorticoid therapy. Increasing the dose of glucocorticoids in such patients often resulted in a second complete response.",
"     </li>",
"     <li>",
"      Severe dysfunction in the skin, liver, or gut at the beginning of treatment was associated with lower incidence of response or improvement in outcome.",
"     </li>",
"     <li>",
"      Less than one-half of patients showed a durable overall improvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results indicate that the potential efficacy of immunosuppressive agents can be assessed meaningfully in patients who have not responded adequately to primary treatment and that more effective treatments are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MATCHED UNRELATED DONOR TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations were almost entirely derived from HLA-identical sibling transplants. Studies of patients with acute GVHD following matched unrelated donor marrow transplantation suggest that more aggressive therapies are warranted since standard treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and ATG is less effective. In a series of 42 such patients from Minnesota, only 9 of 42 patients (21 percent) achieved a complete and continuing response by day +100 after therapy with prednisone and ATG [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/74\">",
"     74",
"    </a>",
"    ]; this is one-half the response seen in patients with HLA-identical sibling donors from the same institution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increase in GVHD following unrelated donor BMT is due to the greater histocompatibility differences between the donor and recipient. Although such patients are often serologically matched, molecular testing reveals that approximately 45 percent of serologic matches are actually mismatched and that the incidence of severe GVHD is higher in the mismatched patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link\">",
"     \"Donor selection for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some suggestion that acute GVHD following matched unrelated donor transplantation may respond to very high doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    . In one series of eight patients, primary therapy of acute GVHD with high dose methylprednisolone (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for four days, with dose escalation to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in nonresponders) was associated with a response in a majority of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/32/6666/abstract/77\">",
"     77",
"    </a>",
"    ]. Unfortunately, this regimen was also associated with severe, life-threatening infectious complications. As an example, three of five patients developed a flare of acute GVHD during steroid dose reduction and died with acute GVHD and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17612833\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Graft-versus-host disease occurs when immune cells transplanted from a non-identical donor (the graft) recognize the transplant recipient (the host) as foreign, thereby initiating an immune reaction that causes disease in the transplant recipient. The pathogenesis of GVHD is a complex, multistep process, but is primarily a T-cell mediated process. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"       \"Pathogenesis of graft-versus-host disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pharmacologic agents used for the prevention and treatment of GVHD include non-specific immunosuppressive drugs, such as corticosteroids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , as well as more specific T-cell immunosuppressive drugs, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , and rapamycin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=see_link\">",
"       \"Prevention and treatment of acute graft-versus-host disease: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids are the first-line therapy for patients who fail prophylaxis (usually with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) and develop acute GVHD. A variety of different glucocorticoid regimens have been evaluated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      being the most commonly used. Initial studies used high doses, but subsequent studies have shown that starting with lower doses is as effective. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standard therapy for steroid refractory GVHD and few randomized clinical trials. Additional agents that have demonstrated activity in acute GVHD include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/57/918?source=see_link\">",
"       denileukin diftitox",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Other approaches'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Phase II trial of available agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monoclonal antibodies directed against T cells, activated T cells, the interleukin-2 receptor (CD25 antigen), adhesion molecules, and tumor necrosis factor-alpha have been evaluated in the treatment of acute GVHD. In almost all trials, the antibodies were used as second-line therapy in patients who did not respond to steroids. As yet, promising results from initial studies have not been confirmed in randomized trials. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Monoclonal antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/1\">",
"      Almawi WY, Lipman ML, Stevens AC, et al. Abrogation of glucocorticoid-mediated inhibition of T cell proliferation by the synergistic action of IL-1, IL-6, and IFN-gamma. J Immunol 1991; 146:3523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/2\">",
"      Antin JH, Ferrara JL. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/3\">",
"      Holler E, Kolb HJ, Wilmanns W. Treatment of GVHD--TNF-antibodies and related antagonists. Bone Marrow Transplant 1993; 12 Suppl 3:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/4\">",
"      Bacigalupo A, van Lint MT, Frassoni F, et al. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983; 46:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/5\">",
"      Kanojia MD, Anagnostou AA, Zander AR, et al. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984; 37:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/6\">",
"      Neudorf S, Filipovich A, Ramsay N, Kersey J. Prevention and treatment of acute graft-versus-host disease. Semin Hematol 1984; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/7\">",
"      Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/8\">",
"      Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 1998; 92:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/9\">",
"      McDonald GB, Bouvier M, Hockenbery DM, et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998; 115:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/10\">",
"      Hockenbery DM, Cruickshank S, Rodell TC, et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109:4557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/11\">",
"      Storb R, Gluckman E, Thomas ED, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974; 44:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/12\">",
"      Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/13\">",
"      Deeg HJ, Loughran TP Jr, Storb R, et al. Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. Transplantation 1985; 40:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/14\">",
"      Tse JC, Moore TB. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease. Pharmacotherapy 1998; 18:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/15\">",
"      Gratama JW, Jansen J, Lipovich RA, et al. Treatment of acute graft-versus-host disease with monoclonal antibody OKT3. Clinical results and effect on circulating T lymphocytes. Transplantation 1984; 38:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/16\">",
"      Gluckman E, Devergie A, Varin F, et al. Treatment of steroid resistant severe acute graft-versus-host disease with a monoclonal pan T OKT3 antibody. Exp Hematol 1984; 12:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/17\">",
"      Hebart H, Ehninger G, Schmidt H, et al. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies. Bone Marrow Transplant 1995; 15:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/18\">",
"      van Oosterhout YV, van Emst L, Schattenberg AV, et al. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease. Blood 2000; 95:3693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/19\">",
"      Vallera DA, Panoskaltsis-Mortari A, Jost C, et al. Anti-graft-versus-host disease effect of DT390-anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor. Blood 1996; 88:2342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/20\">",
"      Martin PJ, Nelson BJ, Appelbaum FR, et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 1996; 88:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/21\">",
"      Herv&eacute; P, Wijdenes J, Bergerat JP, et al. Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10). Blood 1990; 75:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/22\">",
"      Wijdenes J, Beliard R, Muot S, et al. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study. Dev Biol Stand 1990; 71:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/23\">",
"      Herve P, Bordigoni P, Cahn JY, et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation. Transplant Proc 1991; 23:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/24\">",
"      Tiberghien P, Racadot E, Lioure B, et al. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. Transplantation 1991; 52:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/25\">",
"      Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood 1994; 84:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/26\">",
"      Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000; 95:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/27\">",
"      Bordigoni P, Dimicoli S, Clement L, et al. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Haematol 2006; 135:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/28\">",
"      Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004; 124:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/29\">",
"      Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 2004; 104:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/30\">",
"      Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005; 130:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/31\">",
"      Bay JO, Dh&eacute;din N, Goerner M, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005; 80:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/32\">",
"      Herv&eacute; P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79:3362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/33\">",
"      Herve P. Perspectives in the prevention and treatment of acute graft versus host disease. Bone Marrow Transplant 1991; 7 Suppl 2:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/34\">",
"      Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/35\">",
"      Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/36\">",
"      Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/37\">",
"      Schnitzler M, Hasskarl J, Egger M, et al. Successful treatment of severe acute intestinal graft-versus-host resistant to systemic and topical steroids with alemtuzumab. Biol Blood Marrow Transplant 2009; 15:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/38\">",
"      Deeg HJ, Blazar BR, Bolwell BJ, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001; 98:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/39\">",
"      Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2007; 109:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/40\">",
"      Racadot E, Milpied N, Bordigoni P, et al. Sequential use of three monoclonal antibodies in corticosteroid-resistant acute GVHD: a multicentric pilot study including 15 patients. Bone Marrow Transplant 1995; 15:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/41\">",
"      Basara N, Blau WI, R&ouml;mer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/42\">",
"      Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant 2009; 44:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/43\">",
"      Vogelsang G, Taylor S, Gordon G, et al. Thalidomide, a potent agent for the treatment of graft-versus-host disease. Transplant Proc 1986; 18:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/44\">",
"      Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 86:3604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/45\">",
"      Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/46\">",
"      Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002; 100:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/47\">",
"      Setterblad N, Garban F, Weigl R, et al. Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death. Transfusion 2008; 48:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/48\">",
"      Marshall SR. Technology insight: ECP for the treatment of GvHD--can we offer selective immune control without generalized immunosuppression? Nat Clin Pract Oncol 2006; 3:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/49\">",
"      Besnier DP, Chabannes D, Mah&eacute; B, et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy: a pilot study. Transplantation 1997; 64:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/50\">",
"      Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease. Biol Blood Marrow Transplant 1998; 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/51\">",
"      Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/52\">",
"      Kanold J, Merlin E, Halle P, et al. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature. Transfusion 2007; 47:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/53\">",
"      Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/54\">",
"      Dall'Amico R, Messina C. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Ther Apher 2002; 6:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/55\">",
"      Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/56\">",
"      Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005; 11:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/57\">",
"      Bola&ntilde;os-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 2005; 23:2661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/58\">",
"      Chiang KY, Abhyankar S, Bridges K, et al. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 2002; 73:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/59\">",
"      Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/60\">",
"      Kennedy GA, Butler J, Western R, et al. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease. Bone Marrow Transplant 2006; 37:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/61\">",
"      Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005; 35:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/62\">",
"      Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 2008; 111:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/63\">",
"      Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/64\">",
"      Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 2012; 119:3854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/65\">",
"      Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/66\">",
"      Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008; 371:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/67\">",
"      Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/68\">",
"      Ringd&eacute;n O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/69\">",
"      Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/70\">",
"      Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/71\">",
"      Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/72\">",
"      Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation 1994; 58:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/73\">",
"      Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991; 77:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/74\">",
"      Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant 1992; 10:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/75\">",
"      Speiser DE, Tiercy JM, Rufer N, et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. Blood 1996; 87:4455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/76\">",
"      Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998; 339:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/32/6666/abstract/77\">",
"      Oblon DJ, Felker D, Coyle K, Myers L. High-dose methylprednisolone therapy for acute graft-versus-host disease associated with matched unrelated donor bone marrow transplantation. Bone Marrow Transplant 1992; 10:355.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3543 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6666=[""].join("\n");
var outline_f6_32_6666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17612833\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Beclomethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTITHYMOCYTE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TACROLIMUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MONOCLONAL ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OKT3 and anti-CD3 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anti-CD3 and anti-CD5 immunotoxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anti-interleukin-2 receptor antibodies (daclizumab)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anti-tumor necrosis factor-alpha antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Extracorporeal photochemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Denileukin diftitox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pentostatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Etanercept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Phase II trial of available agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MESENCHYMAL STEM CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Steroid-resistant acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Use with steroids in acute GVHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATIENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MATCHED UNRELATED DONOR TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17612833\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/52/4938?source=related_link\">",
"      Acute renal allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=related_link\">",
"      Investigational immunosuppressive drugs and approaches in clinical kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/1/34842?source=related_link\">",
"      Overview of immunosuppressive agents used for prevention and treatment of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/11/10425?source=related_link\">",
"      Prevention and treatment of acute graft-versus-host disease: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/35/35385?source=related_link\">",
"      Treatment of chronic graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_32_6667="Clinical clues DISH";
var content_f6_32_6667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical clues to the presence of diffuse idiopathic skeletal hyperostosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Generalized tenderness at peripheral entheses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent Achilles tendinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent shoulder \"bursitis\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent lateral or medial epicondylitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpable bony spurs (calcaneus, olecranon, patella)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft tissue mass adherent to quadriceps, patella, or Achilles tendon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysphagia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis 1985; 11:325. Copyright &copy;1985 WB Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6667=[""].join("\n");
var outline_f6_32_6667=null;
var title_f6_32_6668="ADR types AB";
var content_f6_32_6668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of adverse drug reactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug reaction",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Reactions occurring in most normal patients, given sufficient dose and duration of therapy (type A)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Overdose",
"       </td>",
"       <td>",
"        Hepatic failure (acetaminophen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Side effects",
"       </td>",
"       <td>",
"        Nausea, headache (with methylxanthines)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Secondary or indirect effects",
"       </td>",
"       <td>",
"        GI bacterial alteration after antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drug interactions",
"       </td>",
"       <td>",
"        Erythromycin increasing theophylline/digoxin blood levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Drug hypersensitivity reactions restricted to a small subset of the general population (type B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intolerance*",
"       </td>",
"       <td>",
"        Tinnitus after a single aspirin tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Idiosyncrasy",
"        <sup>",
"         &bull;",
"        </sup>",
"        (pharmacogenetics)",
"       </td>",
"       <td>",
"        G6PD deficiency: anemia after antioxidant drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Immunologic drug reactions (allergy)",
"       </td>",
"       <td>",
"        Anaphylaxis from beta-lactam antibiotics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GI: gastrointestinal; G6PD: glucose-6-phosphate dehydrogenase.",
"     <br>",
"      * Side effects at subtherapeutic doses.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Drug effect not attributable to known pharmacologic properties of drug and not immune medicated.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Celik G, Pichler WJ, Adkinson NF Jr. Drug Allergy. In: Middleton's Allergy Principles &amp; Practice, 7th ed, Adkinson NF, et al (Ed), Mosby Elsevier, Philadelphia 2009. p.1205-1226. Illustration used with permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6668=[""].join("\n");
var outline_f6_32_6668=null;
var title_f6_32_6669="Generation of osmotic pressure";
var content_f6_32_6669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generation of osmotic pressure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 414px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of adding an impermeable solute such as glucose to the fluid on one side of a membrane that is permeable to water. As water moves into the glucose compartment down a favorable osmotic gradient, a hydrostatic pressure is generated (measured by the height of the column of water above the glucose compartment) which at equilibrium will be equal to the osmotic pressure of the solution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6669=[""].join("\n");
var outline_f6_32_6669=null;
var title_f6_32_6670="Incubation period for rash I";
var content_f6_32_6670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66762%7EID%2F81858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66762%7EID%2F81858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incubation period for infectious diseases associated with fever and rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent/disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arcanobacterium haemolyticum",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atypical measles",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blastomyces dermatitidis",
"       </td>",
"       <td>",
"        30-45 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Boutonneuse fever (Rickettsia conorii)",
"       </td>",
"       <td>",
"        6-10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cat scratch disease",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chancroid",
"       </td>",
"       <td>",
"        1-35 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chickenpox",
"       </td>",
"       <td>",
"        10-20 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlamydia psittaci",
"       </td>",
"       <td>",
"        5-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coccidioides immitis",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxsackie/echovirus",
"       </td>",
"       <td>",
"        2-9 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous larva migrans",
"       </td>",
"       <td>",
"        2-4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dengue",
"       </td>",
"       <td>",
"        3-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated gonococcal infection",
"       </td>",
"       <td>",
"        5 days - several months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichiosis",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escherichia coli 0157:H7",
"       </td>",
"       <td>",
"        3-8 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epstein-Barr virus (mononucleosis)",
"       </td>",
"       <td>",
"        30-50 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gnathostomiasis",
"       </td>",
"       <td>",
"        3-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granuloma inguinale",
"       </td>",
"       <td>",
"        8-80 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B",
"       </td>",
"       <td>",
"        45-160 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis C",
"       </td>",
"       <td>",
"        14-180 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes simplex (genital)",
"       </td>",
"       <td>",
"        2-7 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immunodeficiency virus (HIV)",
"       </td>",
"       <td>",
"        28-180 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kawasaki syndrome",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leishmaniasis",
"       </td>",
"       <td>",
"        14-56 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loiasis",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        3-30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphogranuloma venerum (LGV)",
"       </td>",
"       <td>",
"        3-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium leprae",
"       </td>",
"       <td>",
"        &gt;1 year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycobacterium marinum",
"       </td>",
"       <td>",
"        14-56 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incubation period for infectious diseases associated with fever and rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent/disease",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incubation period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mycoplasma pneumoniae",
"       </td>",
"       <td>",
"        7-28 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neisseria meningitidis",
"       </td>",
"       <td>",
"        1-10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Onchocerciasis",
"       </td>",
"       <td>",
"        6-12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parvovirus B19",
"       </td>",
"       <td>",
"        7-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reiter's syndrome",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relapsing fever",
"       </td>",
"       <td>",
"        4-18 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatic fever",
"       </td>",
"       <td>",
"        7-35 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rickettsialpox, Rickettsia akari",
"       </td>",
"       <td>",
"        10-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rocky Mountain spotted fever, Rickettsia rickettsii",
"       </td>",
"       <td>",
"        2-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Roseola infantum",
"       </td>",
"       <td>",
"        5-15 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella",
"       </td>",
"       <td>",
"        5-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubeola",
"       </td>",
"       <td>",
"        10-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmonella typhi (enteric fever)",
"       </td>",
"       <td>",
"        3-60 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirillum minus",
"       </td>",
"       <td>",
"        7-24 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sporothrix schenckii",
"       </td>",
"       <td>",
"        7-30 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcal toxic shock syndrome",
"       </td>",
"       <td>",
"        2 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptobacillus moniliformis",
"       </td>",
"       <td>",
"        3-22 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syphilis",
"       </td>",
"       <td>",
"        9-90 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasma gondii",
"       </td>",
"       <td>",
"        4-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trypanosoma cruzi",
"       </td>",
"       <td>",
"        5-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tularemia",
"       </td>",
"       <td>",
"        1-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: endemic flea-borne, Rickettsia typhi",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: epidemic louse-borne, Rickettsia prowazekii",
"       </td>",
"       <td>",
"        7-14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typhus: scrub, Rickettsia orientalis/Rickettsia tsutsugamushi",
"       </td>",
"       <td>",
"        6-21 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vibrio vulnificus",
"       </td>",
"       <td>",
"        1-4 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        2-8 days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with&nbsp;fever and rash. In: The Skin and Infection: A Color Atlas and Text,&nbsp;Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6670=[""].join("\n");
var outline_f6_32_6670=null;
var title_f6_32_6671="ROP Plus disease";
var content_f6_32_6671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plus disease in retinopathy of prematurity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In plus disease, the blood vessels in the posterior pole of the retina appear dilated and tortuous.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_32_6671=[""].join("\n");
var outline_f6_32_6671=null;
